Neuroprotection beyond neurons: integrated biomarker-based and astroglia- or microglia-targeted approaches to combat neurodegenerative diseases

Cinzia Volonté , Guoku Hu , Christopher A. Shaw , Claudio Viegas Jr. , Joyce Alves dos Santos , Sandra H. Vaz , Ana M. Sebastião , Vladimir J. Balcar , P. David Mozley , Federico Verde , Vincenzo Silani , Fernanda Tibolla Viero , Yong Tang , Henning Ulrich , Rafael Franco

Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) : 1004136

PDF (5015KB)
Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) :1004136 DOI: 10.37349/ent.2026.1004136
Review
research-article
Neuroprotection beyond neurons: integrated biomarker-based and astroglia- or microglia-targeted approaches to combat neurodegenerative diseases
Author information +
History +
PDF (5015KB)

Abstract

Neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Huntington’s, and Amyotrophic Lateral Sclerosis, are characterized by multifactorial pathologies that extend beyond neuronal loss to include neuroinflammation, oxidative stress, mitochondrial dysfunction, and glial dysregulation. Despite extensive research, disease-modifying therapies remain elusive, hindered by late diagnosis, limited availability of specific biomarkers, and the persistent dominance of reductionist, single-target strategies. This comprehensive and informative review provides a critical synthesis of integrated neuroprotective strategies, with particular focus on glial mechanisms and biomarker-guided interventions. Therapeutic emphasis is placed on coordinated mechanisms targeting both neurons and non-neuronal cells, such as astrocytes, microglia, and oligodendrocytes. Emerging strategies are reported to include modulation of synaptic plasticity and neurotransmission, delivery of neurotrophic factors, activation of intrinsic cytoprotective pathways (e.g., Nrf2 signaling), restoration of proteostasis, and induction of regeneration via cellular reprogramming. Glial cells are discussed as therapeutic targets involved in inflammation, metabolism, myelination, and neuronal survival. Advances in predictive, preventive, personalized, and participatory (P4) medicine, supported by genomics, multi-omics, imaging, and real-world data, are presented as accelerating biomarker discovery and enabling earlier and more precise stage-specific interventions. Future success in combating neurodegeneration will depend on integrated approaches that combine protective, supportive, and regenerative strategies, appropriate for disease stage and patient profile. By reframing neuroprotection as a systemic, multicellular endeavor, this review highlights the potential to not only extend life expectancy, but also preserve meaningful quality of life in individuals affected by neurodegenerative diseases.

Keywords

Alzheimer’s disease / Huntington’s disease / Parkinson’s disease / amyotrophic lateral sclerosis / P4 medicine / proteomics / metabolomics

Cite this article

Download citation ▾
Cinzia Volonté, Guoku Hu, Christopher A. Shaw, Claudio Viegas Jr., Joyce Alves dos Santos, Sandra H. Vaz, Ana M. Sebastião, Vladimir J. Balcar, P. David Mozley, Federico Verde, Vincenzo Silani, Fernanda Tibolla Viero, Yong Tang, Henning Ulrich, Rafael Franco. Neuroprotection beyond neurons: integrated biomarker-based and astroglia- or microglia-targeted approaches to combat neurodegenerative diseases. Exploration of Neuroprotective Therapy, 2026, 6 (1) : 1004136 DOI:10.37349/ent.2026.1004136

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Liu K, Zhang K, Hu A, Li Y, Qin H, Sun W, et al. Global burden of motor neuron disease: unraveling socioeconomic disparities, aging dynamics, and divergent future trajectories (1990-2040). J Neurol. 2025; 272: 390.

[2]

Collaborators G2NSD. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024; 23: 344-81.

[3]

Fahn S. The 200-year journey of Parkinson disease: Reflecting on the past and looking towards the future. Parkinsonism Relat Disord. 2018; 46 Suppl 1: S1-5.

[4]

Hornykiewicz O. The discovery of dopamine deficiency in the parkinsonian brain. J Neural Transm Suppl. 2006; 9-15.

[5]

Sivanandy P, Leey TC, Xiang TC, Ling TC, Han SAW, Semilan SLA, et al. Systematic Review on Parkinson's Disease Medications, Emphasizing on Three Recently Approved Drugs to Control Parkinson’s Symptoms. Int J Environ Res Public Health. 2021; 19: 364.

[6]

Richmond AM, Lyons KE, Pahwa R. Safety review of current pharmacotherapies for levodopa-treated patients with Parkinson’s disease. Expert Opin Drug Saf. 2023; 22: 563-79.

[7]

Cogan G, Daida K, Blauwendraat C, Billingsley K, Brice A. Exploration of Neurodegenerative Diseases Using Long-Read Sequencing and Optical Genome Mapping Technologies. Mov Disord. 2025; 40: 996-1008.

[8]

Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017; 3: 17013.

[9]

Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet. 2021; 397: 2284-303.

[10]

Alam MR, Singh S. Neuromodulation in Parkinson’s disease targeting opioid and cannabinoid receptors, understanding the role of NLRP3 pathway: a novel therapeutic approach. Inflammopharmacology. 2023; 31: 1605-27.

[11]

Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis. 2010; 37: 510-8.

[12]

Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol. 2009; 8: 382-97.

[13]

Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017; 18: 435-50.

[14]

Tran J, Anastacio H, Bardy C. Genetic predispositions of Parkinson’s disease revealed in patient-derived brain cells. NPJ Parkinsons Dis. 2020; 6: 8.

[15]

Franco R. Science plus technology to address challenges in determining the efficacy of neuroprotective/neurorestorative therapies. Explor Neuroprot Ther. 2021; 1: 1-6.

[16]

Long JM, Holtzman DM. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell. 2019; 179: 312-39.

[17]

Henstridge CM, Hyman BT, Spires-Jones TL. Beyond the neuron-cellular interactions early in Alzheimer disease pathogenesis. Nat Rev Neurosci. 2019; 20: 94-108.

[18]

Cummings J, Lee G, Nahed P, Kambar MEZN, Zhong K, Fonseca J, et al. Alzheimer’s disease drug development pipeline: 2022. Alzheimers Dement (N Y). 2022; 8: e12295.

[19]

van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023; 388: 9-21.

[20]

Aron L, Ngian ZK, Qiu C, Choi J, Liang M, Drake DM, et al. Lithium deficiency and the onset of Alzheimer’s disease. Nature. 2025; 645: 712-21.

[21]

Wiseman AL, Briggs CA, Peritt A, Kapecki N, Peterson DA, Shim SS, et al. Lithium Provides Broad Therapeutic Benefits in an Alzheimer's Disease Mouse Model. J Alzheimers Dis. 2023; 91: 273-90.

[22]

Nunes MA, Schöwe NM, Monteiro-Silva KC, Baraldi-Tornisielo T, Souza SIG, Balthazar J, et al. Chronic Microdose Lithium Treatment Prevented Memory Loss and Neurohistopathological Changes in a Transgenic Mouse Model of Alzheimer’s Disease. PLoS One. 2015; 10: e0142267.

[23]

Liu M, Qian T, Zhou W, Tao X, Sang S, Zhao L. Beneficial effects of low-dose lithium on cognitive ability and pathological alteration of Alzheimer's disease transgenic mice model. Neuroreport. 2020; 31: 943-51.

[24]

Bozzali M, D’Amelio M, Serra L. Ventral tegmental area disruption in Alzheimer's disease. Aging (Albany NY). 2019; 11: 1325-6.

[25]

Serra L, D’Amelio M, Esposito S, Domenico CD, Koch G, Marra C, et al. Ventral Tegmental Area Disconnection Contributes Two Years Early to Correctly Classify Patients Converted to Alzheimer's Disease: Implications for Treatment. J Alzheimers Dis. 2021; 82: 985-1000.

[26]

D’Amelio M, Serra L, Bozzali M. Ventral Tegmental Area in Prodromal Alzheimer’s Disease: Bridging the Gap between Mice and Humans. J Alzheimers Dis. 2018; 63: 181-3.

[27]

Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011; 7: 280-92.

[28]

Strooper BD, Karran E. The Cellular Phase of Alzheimer’s Disease. Cell. 2016; 164: 603-15.

[29]

Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, et al. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease. Cell. 2017; 170: 649-63.e13.

[30]

Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer’s disease. J Cell Biol. 2018; 217: 459-72.

[31]

Swerdlow RH, Burns JM, Khan SM. The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta. 2014; 1842: 1219-31.

[32]

Nixon RA. Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer’s disease: inseparable partners in a multifactorial disease. FASEB J. 2017; 31: 2729-43.

[33]

Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2020. Alzheimers Dement (N Y). 2020; 6: e12050.

[34]

Reed S, Taka E, Darling-Reed S, Soliman KFA. Neuroprotective Effects of Metformin Through the Modulation of Neuroinflammation and Oxidative Stress. Cells. 2025; 14: 1064.

[35]

Brewer JB. Fully-automated volumetric MRI with normative ranges: translation to clinical practice. Behav Neurol. 2009; 21: 21-8.

[36]

Walker FO. Huntington’s disease. Lancet. 2007; 369: 218-28.

[37]

Reilmann R, Leavitt BR, Ross CA. Diagnostic criteria for Huntington’s disease based on natural history. Mov Disord. 2014; 29: 1335-41.

[38]

Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington’s disease. Lancet Neurol. 2017; 16: 837-47.

[39]

Ross CA, Tabrizi SJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011; 10: 83-98.

[40]

Vonsattel JPG, Keller C, Amaya MDP. Neuropathology of Huntington’s disease. Handb Clin Neurol. 2008; 89: 599-618.

[41]

McColgan P, Tabrizi SJ. Huntington’s disease: a clinical review. Eur J Neurol. 2018; 25: 24-34.

[42]

Saudou F, Humbert S. The Biology of Huntingtin. Neuron. 2016; 89: 910-26.

[43]

Raymond LA, André VM, Cepeda C, Gladding CM, Milnerwood AJ, Levine MS. Pathophysiology of Huntington’s disease: time-dependent alterations in synaptic and receptor function. Neuroscience. 2011; 198: 252-73.

[44]

Suchowersky O, Armstrong MJ, Miyasaki J. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the Guideline Development Subcommittee of the American Academy of Neurology . Neurology. 2013; 80: 970.

[45]

Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, et al. Targeting Huntingtin Expression in Patients with Huntington’s Disease. N Engl J Med. 2019; 380: 2307-16.

[46]

Sah DWY, Aronin N. Oligonucleotide therapeutic approaches for Huntington disease. J Clin Invest. 2011; 121: 500-7.

[47]

Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease. J Exp Med. 2008; 205: 1869-77.

[48]

Hsiao H, Chen Y, Huang C, Chen C, Hsu Y, Chen H, et al. Aberrant astrocytes impair vascular reactivity in Huntington disease. Ann Neurol. 2015; 78: 178-92.

[49]

Crotti A, Glass CK. The choreography of neuroinflammation in Huntington’s disease. Trends Immunol. 2015; 36: 364-73.

[50]

Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 2006; 127: 59-69.

[51]

Martinez-Vicente M, Talloczy Z, Wong E, Tang G, Koga H, Kaushik S, et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington’s disease. Nat Neurosci. 2010; 13: 567-76.

[52]

Shirendeb UP, Calkins MJ, Manczak M, Anekonda V, Dufour B, McBride JL, et al. Mutant huntingtin’s interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington’s disease. Hum Mol Genet. 2012; 21: 406-20.

[53]

Al-Wardat M, Schirinzi T, Hadoush H, Kassab M, Yabroudi MA, Opara J, et al. Home-Based Exercise to Improve Motor Functions, Cognitive Functions, and Quality of Life in People with Huntington’s Disease: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2022; 19: 14915.

[54]

McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, et al.; Huntington Study Group 2CARE Investigators and Coordinators. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017; 88: 152-9.

[55]

Tabrizi SJ, Estevez-Fraga C, van Roon-Mom WMC, Flower MD, Scahill RI, Wild EJ, et al. Potential disease-modifying therapies for Huntington’s disease: lessons learned and future opportunities. Lancet Neurol. 2022; 21: 645-58.

[56]

Southwell AL, Kordasiewicz HB, Langbehn D, Skotte NH, Parsons MP, Villanueva EB, et al. Huntingtin suppression restores cognitive function in a mouse model of Huntington’s disease. Sci Transl Med. 2018; 10: eaar3959.

[57]

Mueller A, Paterson E, McIntosh A, Praestgaard J, Bylo M, Hoefling H, et al. Digital endpoints for self-administered home-based functional assessment in pediatric Friedreich’s ataxia. Ann Clin Transl Neurol. 2021; 8: 1845-56.

[58]

Byrne LM, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RAC, et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis. Lancet Neurol. 2017; 16: 601-9.

[59]

Riva N, Domi T, Pozzi L, Lunetta C, Schito P, Spinelli EG, et al. Update on recent advances in amyotrophic lateral sclerosis. J Neurol. 2024; 271: 4693-723.

[60]

Nijs M, Damme PV. The genetics of amyotrophic lateral sclerosis. Curr Opin Neurol. 2024; 37: 560-9.

[61]

Newell ME, Adhikari S, Halden RU. Systematic and state-of the science review of the role of environmental factors in Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig’s Disease. Sci Total Environ. 2022; 817: 152504.

[62]

Maggio R, Fasciani I, Coppolino MF, Petragnano F, Rossi M. Sounding the alarm: Could stadium crowd noise contribute to amyotrophic lateral sclerosis risk in soccer and football players? Med Hypotheses. 2025; 202: 111732.

[63]

French PW, Ludowyke R, Guillemin GJ. Fungal Neurotoxins and Sporadic Amyotrophic Lateral Sclerosis. Neurotox Res. 2019; 35: 969-80.

[64]

Sathasivam S. VEGF and ALS. Neurosci Res. 2008; 62: 71-7.

[65]

Re DB, Yan B, Calderón-Garcidueñas L, Andrew AS, Tischbein M, Stommel EW. A perspective on persistent toxicants in veterans and amyotrophic lateral sclerosis: identifying exposures determining higher ALS risk. J Neurol. 2022; 269: 2359-77.

[66]

Gamez J, Carmona F. Confirmation of early non-bulbar onset of amyotrophic lateral sclerosis in Spanish league soccer players. J Neurol Sci. 2021; 428: 117586.

[67]

Pupillo E, Bianchi E, Vanacore N, Montalto C, Ricca G, Robustelli Della Cuna FS, et al. Increased risk and early onset of ALS in professional players from Italian Soccer Teams. Amyotroph Lateral Scler Frontotemporal Degener. 2020; 21: 403-9.

[68]

Goutman SA, Boss J, Godwin C, Mukherjee B, Feldman EL, Batterman SA. Occupational history associates with ALS survival and onset segment. Amyotroph Lateral Scler Frontotemporal Degener. 2023; 24: 219-29.

[69]

Feldman EL, Sattler R, Kiernan MC, Goutman SA, Chiò A, Al-Chalabi A. Transforming amyotrophic lateral sclerosis into a liveable disease. Lancet Neurol. 2025; 24: 100-1.

[70]

Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994; 330: 585-91.

[71]

Guiloff RJ, Goonetilleke A, Emami J. Riluzole and amyotrophic lateral sclerosis. Lancet. 1996; 348: 336-7.

[72]

Ludolph AC, Grandjean H, Reviers E, Micheli VD, Bianchi C, Cardosi L, et al. The preferences of people with amyotrophic lateral sclerosis on riluzole treatment in Europe. Sci Rep. 2023; 13: 22497.

[73]

Corcia P, Guy N, Pradat P, Soriani M, Verschueren A, Couratier P. Treatment continuity of amyotrophic lateral sclerosis with available riluzole formulations: state of the art and current challenges in a ‘real-world’ setting. Amyotroph Lateral Scler Frontotemporal Degener. 2025; 26: 15-21.

[74]

Neupane P, Thada PK, Singh P, Faisal AR, Rai N, Poudel P, et al. Investigating Edaravone Use for Management of Amyotrophic Lateral Sclerosis (ALS): A Narrative Review. Cureus. 2023; 15: e33746.

[75]

O’Neill R, Yoo O, Burcham P, Lim LY. Edaravone for the Treatment of Motor Neurone Disease: A Critical Review of Approved and Alternative Formulations against a Proposed Quality Target Product Profile. Pharmaceutics. 2024; 16: 993.

[76]

Mullard A. ALS antisense drug falters in phase III. Nat Rev Drug Discov. 2021; 20: 883-5.

[77]

Everett WH, Bucelli RC. Tofersen for SOD1 ALS. Neurodegener Dis Manag. 2024; 14: 149-60.

[78]

Lovett A, Chary S, Babu S, Bruneteau G, Glass JD, Karlsborg M, et al. Serious Neurologic Adverse Events in Tofersen Clinical Trials for Amyotrophic Lateral Sclerosis. Muscle Nerve. 2025; 71: 1006-15.

[79]

Goldshtein H, Muhire A, Légaré VP, Pushett A, Rotkopf R, Shefner JM, et al. Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020; 7: 1883-97.

[80]

Salomon-Zimri S, Kerem N, Linares GR, Russek-Blum N, Ichida JK, Tracik F. Elucidating the Synergistic Effect of the PrimeC Combination for Amyotrophic Lateral Sclerosis in Human Induced Pluripotent Stem Cell-Derived Motor Neurons and Mouse Models. Pharmaceuticals (Basel). 2025; 18: 524.

[81]

Meyer M, Meijer O, Hunt H, Belanoff J, Lima A, de Kloet ER, et al. Stress-induced Neuroinflammation of the Spinal Cord is Restrained by Cort113176 (Dazucorilant), A Specific Glucocorticoid Receptor Modulator. Mol Neurobiol. 2024; 61: 1-14.

[82]

Parmar DV, Kansagra KA, Momin T, Patel HB, Jansari GA, Bhavsar J, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First-in-Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose). Clin Pharmacol Drug Dev. 2023; 12: 202-11.

[83]

Yeole A, Khanna L, Doshi M, Sharma A, Uttarwar P, Doshi S, et al. A phase 2, proof-of-concept, placebo-controlled, randomized, multicenter, double-blind study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of Usnoflast (ZYIL1) in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2025; 26: 794-801.

[84]

Moretti A, Ferrari F, Villa RF. Neuroprotection for ischaemic stroke: current status and challenges. Pharmacol Ther. 2015; 146: 23-34.

[85]

Nakintu A, Vicario CM, Wang L, Luan S, Qi F. Effects of Motor Imagery Combined With Action Observation on Motor Function in Stroke Patients. J Integr Neurosci. 2025; 24: 26495.

[86]

Wang W, Wang H, Zhao R. The burden of stroke attributable to ambient particulate matter pollution in China: findings from the Global Burden of Disease Study 2021. Int J Environ Health Res. 2025; 1-14.

[87]

Raina M, Hu J, Shah R, Gilliland M, Rajagopalan S. The health burden of chronic diseases in the United States attributable to air particulate matter. Clin Med (Lond). 2025; 25: 100493.

[88]

Pulciani S, Lonardo AD, Fagnani C, Taruscio D. P4 Medicine versus Hippocrates. Ann Ist Super Sanita. 2017; 53: 185-91.

[89]

Olney JW. Excitotoxicity, apoptosis and neuropsychiatric disorders. Curr Opin Pharmacol. 2003; 3: 101-9.

[90]

Andrew RD, Hartings JA, Ayata C, Brennan KC, Dawson-Scully KD, Farkas E, et al. The Critical Role of Spreading Depolarizations in Early Brain Injury: Consensus and Contention. Neurocrit Care. 2022; 37: 83-101.

[91]

Verma M, Lizama BN, Chu CT. Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration. Transl Neurodegener. 2022; 11: 3.

[92]

Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010; 62: 405-96.

[93]

Suh SW, Aoyama K, Chen Y, Garnier P, Matsumori Y, Gum E, et al. Hypoglycemic neuronal death and cognitive impairment are prevented by poly(ADP-ribose) polymerase inhibitors administered after hypoglycemia. J Neurosci. 2003; 23: 10681-90.

[94]

Cox PA, Kostrzewa RM, Guillemin GJ. BMAA and Neurodegenerative Illness. Neurotox Res. 2018; 33: 178-83.

[95]

Shaw CA, Marler TE. The Lessons of ALS-PDC - Environmental Factors in ALS Etiology. In: Shaw CA, Morrice JR, editors. Spectrums of amyotrophic lateral sclerosis: heterogeneity, pathology, and therapeutic directions. Wiley-Blackwell; 2021. pp. 57-79.

[96]

Spencer PS, Roy DN, Ludolph A, Hugon J, Dwivedi MP, Schaumburg HH. Lathyrism: evidence for role of the neuroexcitatory aminoacid BOAA. Lancet. 1986; 2: 1066-7.

[97]

Rothstein JD, Kammen MV, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol. 1995; 38: 73-84.

[98]

Zheng X, Zhang H, Luo Q, Zhu J. Kainic acid-induced neurodegenerative model: potentials and limitations. J Biomed Biotechnol. 2016; 2016: 457079.

[99]

Blaylock RL, Maroon J. Immunoexcitotoxicity as a central mechanism in chronic traumatic encephalopathy-A unifying hypothesis. Surg Neurol Int. 2011; 2: 107.

[100]

Rae CD, Rowlands BD, Balcar VJ. Aspartate in the Brain: A Review. Neurochem Res. 2025; 50: 199.

[101]

Patneau DK, Mayer ML. Structure-activity relationships for amino acid transmitter candidates acting at N-methyl-D-aspartate and quisqualate receptors. J Neurosci. 1990; 10: 2385-99.

[102]

Kos JA, Langiu M, Hellyer SD, Gregory KJ. Pharmacology, Signaling and Therapeutic Potential of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators. ACS Pharmacol Transl Sci. 2024; 7: 3671-90.

[103]

Ambrosini A, Bresciani L, Fracchia S, Brunello N, Racagni G. Metabotropic glutamate receptors negatively coupled to adenylate cyclase inhibit N-methyl-D-aspartate receptor activity and prevent neurotoxicity in mesencephalic neurons in vitro. Mol Pharmacol. 1995; 47: 1057-64.

[104]

Allen JW, Ivanova SA, Fan L, Espey MG, Basile AS, Faden AI. Group II metabotropic glutamate receptor activation attenuates traumatic neuronal injury and improves neurological recovery after traumatic brain injury. J Pharmacol Exp Ther. 1999; 290: 112-20.

[105]

Faden AI, Ivanova SA, Yakovlev AG, Mukhin AG. Neuroprotective effects of group III mGluR in traumatic neuronal injury. J Neurotrauma. 1997; 14: 885-95.

[106]

McMullan SM, Phanavanh B, Li GG, Barger SW. Metabotropic glutamate receptors inhibit microglial glutamate release. ASN Neuro. 2012; 4: e00094.

[107]

Kritis AA, Stamoula EG, Paniskaki KA, Vavilis TD. Researching glutamate-induced cytotoxicity in different cell lines: a comparative/collective analysis/study. Front Cell Neurosci. 2015; 9: 91.

[108]

Perovic M, Pavlovic D, Palmer Z, Udo MSB, Citadin CT, Rodgers KM, et al. Modulation of GABAergic system as a therapeutic option in stroke. Exp Neurol. 2025; 384: 115050.

[109]

Sebastião AM, Ribeiro JA. Adjusting the brakes to adjust neuronal activity: Adenosinergic modulation of GABAergic transmission. Neuropharmacology. 2023; 236: 109600.

[110]

Dhapola R, Hota SS, Sarma P, Bhattacharyya A, Medhi B, Reddy DH. Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer’s disease. Inflammopharmacology. 2021; 29: 1669-81.

[111]

Yong HYF, Rawji KS, Ghorbani S, Xue M, Yong VW. The benefits of neuroinflammation for the repair of the injured central nervous system. Cell Mol Immunol. 2019; 16: 540-6.

[112]

Mapunda JA, Tibar H, Regragui W, Engelhardt B. How Does the Immune System Enter the Brain? Front Immunol. 2022; 13: 805657.

[113]

Adamu A, Li S, Gao F, Xue G. The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets. Front Aging Neurosci. 2024; 16: 1347987.

[114]

Mészáros Á, Molnár K, Nógrádi B, Hernádi Z, Nyúl-Tóth Á, Wilhelm I, et al. Neurovascular Inflammaging in Health and Disease. Cells. 2020; 9: 1614.

[115]

Balistreri CR, Monastero R. Neuroinflammation and Neurodegenerative Diseases: How Much Do We Still Not Know? Brain Sci. 2023; 14: 19.

[116]

Stephenson J, Nutma E, van der Valk P, Amor S. Inflammation in CNS neurodegenerative diseases. Immunology. 2018; 154: 204-19.

[117]

Allen NJ, Lyons DA. Glia as architects of central nervous system formation and function. Science. 2018; 362: 181-5.

[118]

Lago-Baldaia I, Fernandes VM, Ackerman SD. More Than Mortar: Glia as Architects of Nervous System Development and Disease. Front Cell Dev Biol. 2020; 8: 611269.

[119]

BRAIN Initiative Cell Census Network (BICCN). A multimodal cell census and atlas of the mammalian primary motor cortex. Nature. 2021; 598: 86-102.

[120]

Colonna M, Butovsky O. Microglia Function in the Central Nervous System During Health and Neurodegeneration. Annu Rev Immunol. 2017; 35: 441-68.

[121]

Zhang W, Xiao D, Mao Q, Xia H. Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Ther. 2023; 8: 267.

[122]

Orihuela R, McPherson CA, Harry GJ. Microglial M1/M2 polarization and metabolic states. Br J Pharmacol. 2016; 173: 649-65.

[123]

Franco R, Fernández-Suárez D. Alternatively activated microglia and macrophages in the central nervous system. Prog Neurobiol. 2015; 131: 65-86.

[124]

Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016; 353: 777-83.

[125]

Paolicelli RC, Sierra A, Stevens B, Tremblay M, Aguzzi A, Ajami B, et al. Microglia states and nomenclature: A field at its crossroads. Neuron. 2022; 110: 3458-83.

[126]

Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease. Cell. 2017; 169: 1276-90.e17.

[127]

Olude MA, Mouihate A, Mustapha OA, Farina C, Quintana FJ, Olopade JO. Astrocytes and Microglia in Stress-Induced Neuroinflammation: The African Perspective. Front Immunol. 2022; 13: 795089.

[128]

Patani R, Hardingham GE, Liddelow SA. Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration. Nat Rev Neurol. 2023; 19: 395-409.

[129]

Khakh BS, Sofroniew MV. Diversity of astrocyte functions and phenotypes in neural circuits. Nat Neurosci. 2015; 18: 942-52.

[130]

Vasile F, Dossi E, Rouach N. Human astrocytes: structure and functions in the healthy brain. Brain Struct Funct. 2017; 222: 2017-29.

[131]

Jessen NA, Munk ASF, Lundgaard I, Nedergaard M. The Glymphatic System: A Beginner’s Guide. Neurochem Res. 2015; 40: 2583-99.

[132]

Wang S, Pan Y, Zhang C, Zhao Y, Wang H, Ma H, et al. Transcriptome Analysis Reveals Dynamic Microglial-Induced A1 Astrocyte Reactivity via C3/C3aR/NF-κB Signaling After Ischemic Stroke. Mol Neurobiol. 2024; 61: 10246-70.

[133]

Fan Y, Huo J. A1/A2 astrocytes in central nervous system injuries and diseases: Angels or devils? Neurochem Int. 2021; 148: 105080.

[134]

Rizor A, Pajarillo E, Johnson J, Aschner M, Lee E. Astrocytic Oxidative/Nitrosative Stress Contributes to Parkinson’s Disease Pathogenesis: The Dual Role of Reactive Astrocytes. Antioxidants (Basel). 2019; 8: 265.

[135]

Bolós M, Perea JR, Avila J. Alzheimer’s disease as an inflammatory disease. Biomol Concepts. 2017; 8: 37-43.

[136]

Avila J, Pérez M, Avila-Villanueva M, Santa-María I, Hernández F. Looking at the periphery-new hypothesis to look for new targets for Alzheimer’s disease therapy. Explor Neuroprot Ther. 2023; 3: 151-63.

[137]

Wu Y, Ma Y, Liu Z, Geng Q, Chen Z, Zhang Y. Alterations of myelin morphology and oligodendrocyte development in early stage of Alzheimer’s disease mouse model. Neurosci Lett. 2017; 642: 102-6.

[138]

Kenigsbuch M, Bost P, Halevi S, Chang Y, Chen S, Ma Q, et al. A shared disease-associated oligodendrocyte signature among multiple CNS pathologies. Nat Neurosci. 2022; 25: 876-86.

[139]

Yeung MSY, Djelloul M, Steiner E, Bernard S, Salehpour M, Possnert G, et al. Dynamics of oligodendrocyte generation in multiple sclerosis. Nature. 2019; 566: 538-42.

[140]

Jamet M, Dupuis L, Aguilar JGD. Oligodendrocytes in amyotrophic lateral sclerosis and frontotemporal dementia: the new players on stage. Front Mol Neurosci. 2024; 17: 1375330.

[141]

Mattiola I, Mantovani A, Locati M. The tetraspan MS4A family in homeostasis, immunity, and disease. Trends Immunol. 2021; 42: 764-81.

[142]

Thundyil J, Lim K. DAMPs and neurodegeneration. Ageing Res Rev. 2015; 24: 17-28.

[143]

Sheeler C, Rosa J, Ferro A, McAdams B, Borgenheimer E, Cvetanovic M. Glia in Neurodegeneration: The Housekeeper, the Defender and the Perpetrator. Int J Mol Sci. 2020; 21: 9188.

[144]

Paolicelli RC, Bergamini G, Rajendran L. Cell-to-cell Communication by Extracellular Vesicles: Focus on Microglia. Neuroscience. 2019; 405: 148-57.

[145]

Drago F, Lombardi M, Prada I, Gabrielli M, Joshi P, Cojoc D, et al. ATP Modifies the Proteome of Extracellular Vesicles Released by Microglia and Influences Their Action on Astrocytes. Front Pharmacol. 2017; 8: 910.

[146]

Yun SP, Kam T, Panicker N, Kim S, Oh Y, Park J, et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. Nat Med. 2018; 24: 931-8.

[147]

Rostami J, Mothes T, Kolahdouzan M, Eriksson O, Moslem M, Bergström J, et al. Crosstalk between astrocytes and microglia results in increased degradation of α-synuclein and amyloid-β aggregates. J Neuroinflammation. 2021; 18: 124.

[148]

Nomura Y. Neuronal apoptosis and protection: effects of nitric oxide and endoplasmic reticulum-related proteins. Biol Pharm Bull. 2004; 27: 961-3.

[149]

Balusu S, Horré K, Thrupp N, Craessaerts K, Snellinx A, Serneels L, et al. MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer's disease. Science. 2023; 381: 1176-82.

[150]

Man SM, Karki R, Kanneganti T. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. Immunol Rev. 2017; 277: 61-75.

[151]

Venegas C, Kumar S, Franklin BS, Dierkes T, Brinkschulte R, Tejera D, et al. Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease. Nature. 2017; 552: 355-61.

[152]

Wang S, Yuan YH, Chen NH, Wang HB. The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson’s disease. Int Immunopharmacol. 2019; 67: 458-64.

[153]

Hu Y, Wang B, Li S, Yang S. Pyroptosis, and its Role in Central Nervous System Disease. J Mol Biol. 2022; 434: 167379.

[154]

Wang Y, Mu D, Li Y, Liu C, Feng J, Lai Y, et al. Alzheimer’s disease: a jigsaw puzzle comprised of different types of programmed cell death pieces. Brain Res. 2025; 1865: 149861.

[155]

Nguyen TPM, Alves F, Lane DJR, Bush AI, Ayton S. Triggering ferroptosis in neurodegenerative diseases. Trends Neurosci. 2025; 48: 750-65.

[156]

Araújo B, Caridade-Silva R, Soares-Guedes C, Martins-Macedo J, Gomes ED, Monteiro S, et al. Neuroinflammation and Parkinson's Disease-From Neurodegeneration to Therapeutic Opportunities. Cells. 2022; 11: 2908.

[157]

Demirci-Çekiç S, Özkan G, Avan AN, Uzunboy S, Çapanoğlu E, Apak R. Biomarkers of Oxidative Stress and Antioxidant Defense. J Pharm Biomed Anal. 2022; 209: 114477.

[158]

Salim S. Oxidative Stress and the Central Nervous System. J Pharmacol Exp Ther. 2017; 360: 201-5.

[159]

Singh A, Kukreti R, Saso L, Kukreti S. Oxidative Stress: A Key Modulator in Neurodegenerative Diseases. Molecules. 2019; 24: 1583.

[160]

Tauffenberger A, Magistretti PJ. Reactive Oxygen Species: Beyond Their Reactive Behavior. Neurochem Res. 2021; 46: 77-87.

[161]

Freinbichler W, Colivicchi MA, Stefanini C, Bianchi L, Ballini C, Misini B, et al. Highly reactive oxygen species: detection, formation, and possible functions. Cell Mol Life Sci. 2011; 68: 2067-79.

[162]

Onukwufor JO, Berry BJ, Wojtovich AP. Physiologic Implications of Reactive Oxygen Species Production by Mitochondrial Complex I Reverse Electron Transport. Antioxidants (Basel). 2019; 8: 285.

[163]

Phaniendra A, Jestadi DB, Periyasamy L. Free radicals: properties, sources, targets, and their implication in various diseases. Indian J Clin Biochem. 2015; 30: 11-26.

[164]

Brandes RP, Weissmann N, Schröder K. Nox family NADPH oxidases: Molecular mechanisms of activation. Free Radic Biol Med. 2014; 76: 208-26.

[165]

Konno T, Melo EP, Chambers JE, Avezov E. Intracellular Sources of ROS/H2O2 in Health and Neurodegeneration: Spotlight on Endoplasmic Reticulum. Cells. 2021; 10: 233.

[166]

Li Z, Xu X, Leng X, He M, Wang J, Cheng S, et al. Roles of reactive oxygen species in cell signaling pathways and immune responses to viral infections. Arch Virol. 2017; 162: 603-10.

[167]

Radi R. Oxygen radicals, nitric oxide, and peroxynitrite: Redox pathways in molecular medicine. Proc Natl Acad Sci U S A. 2018; 115: 5839-48.

[168]

Edwards NA, Watson AJ, Betts DH. P66Shc, a key regulator of metabolism and mitochondrial ROS production, is dysregulated by mouse embryo culture. Mol Hum Reprod. 2016; 22: 634-47.

[169]

Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, et al. Oxidative Stress: Harms and Benefits for Human Health. Oxid Med Cell Longev. 2016; 2016: 8416763.

[170]

Kowalczyk P, Sulejczak D, Kleczkowska P, Bukowska-Ośko I, Kucia M, Popiel M, et al. Mitochondrial Oxidative Stress-A Causative Factor and Therapeutic Target in Many Diseases. Int J Mol Sci. 2021; 22: 13384.

[171]

Yang WS, Kim KJ, Gaschler MM, Patel M, Shchepinov MS, Stockwell BR. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci U S A. 2016; 113: E4966-75.

[172]

Butterfield DA. Brain lipid peroxidation and alzheimer disease: Synergy between the Butterfield and Mattson laboratories. Ageing Res Rev. 2020; 64: 101049.

[173]

Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014; 13: 1045-60.

[174]

Ndayisaba A, Kaindlstorfer C, Wenning GK. Iron in Neurodegeneration - Cause or Consequence? Front Neurosci. 2019; 13: 180.

[175]

Baxter PS, Hardingham GE. Adaptive regulation of the brain’s antioxidant defences by neurons and astrocytes. Free Radic Biol Med. 2016; 100: 147-52.

[176]

Ren X, Zou L, Zhang X, Branco V, Wang J, Carvalho C, et al. Redox Signaling Mediated by Thioredoxin and Glutathione Systems in the Central Nervous System. Antioxid Redox Signal. 2017; 27: 989-1010.

[177]

Zeman MK, Cimprich KA. Causes and consequences of replication stress. Nat Cell Biol. 2014; 16: 2-9.

[178]

Peña-Bautista C, Tirle T, López-Nogueroles M, Vento M, Baquero M, Cháfer-Pericás C. Oxidative Damage of DNA as Early Marker of Alzheimer’s Disease. Int J Mol Sci. 2019; 20: 6136.

[179]

Chow H, Herrup K. Genomic integrity and the ageing brain. Nat Rev Neurosci. 2015; 16: 672-84.

[180]

Chaudhary MR, Chaudhary S, Sharma Y, Singh TA, Mishra AK, Sharma S, et al. Aging, oxidative stress and degenerative diseases: mechanisms, complications and emerging therapeutic strategies. Biogerontology. 2023; 24: 609-62.

[181]

Barančík M, Grešová L, Barteková M, Dovinová I. Nrf2 as a key player of redox regulation in cardiovascular diseases. Physiol Res. 2016; 65 Suppl 1: S1-S10.

[182]

Buendia I, Michalska P, Navarro E, Gameiro I, Egea J, León R. Nrf2-ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases. Pharmacol Ther. 2016; 157: 84-104.

[183]

de Freitas Silva M, Pruccoli L, Morroni F, Sita G, Seghetti F, Viegas C, et al. The Keap1/Nrf2-ARE Pathway as a Pharmacological Target for Chalcones. Molecules. 2018; 23: 1803.

[184]

Franco R, Navarro G, Martínez-Pinilla E. Antioxidant Defense Mechanisms in Erythrocytes and in the Central Nervous System. Antioxidants (Basel). 2019; 8: 46.

[185]

Teleanu DM, Niculescu A, Lungu II, Radu CI, Vladâcenco O, Roza E, et al. An Overview of Oxidative Stress, Neuroinflammation, and Neurodegenerative Diseases. Int J Mol Sci. 2022; 23: 5938.

[186]

Birkmayer W, Hornykiewicz O. The L-dihydroxyphenylalanine (L-DOPA) effect in Parkinson's syndrome in man: On the pathogenesis and treatment of Parkinson akinesis. Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr. 1962; 203: 560-74.

[187]

Burbulla LF, Song P, Mazzulli JR, Zampese E, Wong YC, Jeon S, et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease. Science. 2017; 357: 1255-61.

[188]

Höhn A, Tramutola A, Cascella R. Proteostasis Failure in Neurodegenerative Diseases: Focus on Oxidative Stress. Oxid Med Cell Longev. 2016; 2016: 5497046.

[189]

Borsche M, Pereira SL, Klein C, Grünewald A. Mitochondria and Parkinson’s Disease: Clinical, Molecular, and Translational Aspects. J Parkinsons Dis. 2021; 11: 45-60.

[190]

Belvisi D, Pellicciari R, Fabbrini G, Tinazzi M, Berardelli A, Defazio G. Modifiable risk and protective factors in disease development, progression and clinical subtypes of Parkinson’s disease: What do prospective studies suggest? Neurobiol Dis. 2020; 134: 104671.

[191]

Cassidy L, Fernandez F, Johnson JB, Naiker M, Owoola AG, Broszczak DA. Oxidative stress in alzheimer’s disease: A review on emergent natural polyphenolic therapeutics. Complement Ther Med. 2020; 49: 102294.

[192]

Butterfield DA, Halliwell B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci. 2019; 20: 148-60.

[193]

Simunkova M, Alwasel SH, Alhazza IM, Jomova K, Kollar V, Rusko M, et al. Management of oxidative stress and other pathologies in Alzheimer’s disease. Arch Toxicol. 2019; 93: 2491-513.

[194]

Rajendran R, Minqin R, Ynsa MD, Casadesus G, Smith MA, Perry G, et al. A novel approach to the identification and quantitative elemental analysis of amyloid deposits--insights into the pathology of Alzheimer’s disease. Biochem Biophys Res Commun. 2009; 382: 91-5.

[195]

Franco R, Navarro G, Martínez-Pinilla E. Lessons on Differential Neuronal-Death-Vulnerability from Familial Cases of Parkinson’s and Alzheimer’s Diseases. Int J Mol Sci. 2019; 20: 3297.

[196]

Zheng J, Winderickx J, Franssens V, Liu B. A Mitochondria-Associated Oxidative Stress Perspective on Huntington's Disease. Front Mol Neurosci. 2018; 11: 329.

[197]

Brustovetsky N. Mutant Huntingtin and Elusive Defects in Oxidative Metabolism and Mitochondrial Calcium Handling. Mol Neurobiol. 2016; 53: 2944-53.

[198]

Motataianu A, Serban G, Barcutean L, Balasa R. Oxidative Stress in Amyotrophic Lateral Sclerosis: Synergy of Genetic and Environmental Factors. Int J Mol Sci. 2022; 23: 9339.

[199]

Cascella R, Fani G, Bigi A, Chiti F, Cecchi C. Partial Failure of Proteostasis Systems Counteracting TDP-43 Aggregates in Neurodegenerative Diseases. Int J Mol Sci. 2019; 20: 3685.

[200]

Sweeney MD, Kisler K, Montagne A, Toga AW, Zlokovic BV. The role of brain vasculature in neurodegenerative disorders. Nat Neurosci. 2018; 21: 1318-31.

[201]

Knopp RC, Jastaniah A, Dubrovskyi O, Gaisina I, Tai L, Thatcher GRJ. Extending the Calpain-Cathepsin Hypothesis to the Neurovasculature: Protection of Brain Endothelial Cells and Mice from Neurotrauma. ACS Pharmacol Transl Sci. 2021; 4: 372-85.

[202]

Wilson DM 3rd, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I. Hallmarks of neurodegenerative diseases. Cell. 2023; 186: 693-714.

[203]

Lynch MA. Long-term potentiation and memory. Physiol Rev. 2004; 84: 87-136.

[204]

Henstridge CM, Pickett E, Spires-Jones TL. Synaptic pathology: A shared mechanism in neurological disease. Ageing Res Rev. 2016; 28: 72-84.

[205]

Bredt DS, Nicoll RA. AMPA receptor trafficking at excitatory synapses. Neuron. 2003; 40: 361-79.

[206]

Kadriu B, Musazzi L, Johnston JN, Kalynchuk LE, Caruncho HJ, Popoli M, et al. Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road. Drug Discov Today. 2021; 26: 2816-38.

[207]

Lauterborn JC, Lynch G, Vanderklish P, Arai A, Gall CM. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci. 2000; 20: 8-21.

[208]

Xue J, Masuoka T, Gong X, Chen K, Yanagawa Y, Law SKA, et al. NMDA receptor activation enhances inhibitory GABAergic transmission onto hippocampal pyramidal neurons via presynaptic and postsynaptic mechanisms. J Neurophysiol. 2011; 105: 2897-906.

[209]

Wu W, Gong X, Qin Z, Wang Y. Molecular mechanisms of excitotoxicity and their relevance to the pathogenesis of neurodegenerative diseases-an update. Acta Pharmacol Sin. 2025; 46: 3129-42.

[210]

Dong X, Wang Y, Qin Z. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin. 2009; 30: 379-87.

[211]

Rodríguez-Ruiz M, Moreno E, Moreno-Delgado D, Navarro G, Mallol J, Cortés A, et al. Heteroreceptor Complexes Formed by Dopamine D1, Histamine H3, and N-Methyl-D-Aspartate Glutamate Receptors as Targets to Prevent Neuronal Death in Alzheimer's Disease. Mol Neurobiol. 2017; 54: 4537-50.

[212]

Wu C, Hu H, Chow L, Chou Y, Huang N, Wang P, et al. The Effects of Anti-Dementia and Nootropic Treatments on the Mortality of Patients with Dementia: A Population-Based Cohort Study in Taiwan. PLoS One. 2015; 10: e0130993.

[213]

Wang R, Reddy PH. Role of Glutamate and NMDA Receptors in Alzheimer’s Disease. J Alzheimers Dis. 2017; 57: 1041-8.

[214]

Lao K, Ji N, Zhang X, Qiao W, Tang Z, Gou X. Drug development for Alzheimer’s disease: review. J Drug Target. 2019; 27: 164-73.

[215]

Singh P, Paramanik V. DNA methylation, histone acetylation in the regulation of memory and its modulation during aging. Front Aging. 2025; 5: 1480932.

[216]

Geng H, Chen H, Wang H, Wang L. The Histone Modifications of Neuronal Plasticity. Neural Plast. 2016; 2016: 6690523.

[217]

Baik S, Rajeev V, Fann DY, Jo D, Arumugam TV. Intermittent fasting increases adult hippocampal neurogenesis. Brain Behav. 2020; 10:e01444.

[218]

Sleiman SF, Henry J, Al-Haddad R, Hayek LE, Haidar EA, Stringer T, et al. Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body β-hydroxybutyrate. Elife. 2016; 5: e15092.

[219]

Gudden J, Vasquez AA, Bloemendaal M. The Effects of Intermittent Fasting on Brain and Cognitive Function. Nutrients. 2021; 13: 3166.

[220]

Kricheldorff J, Göke K, Kiebs M, Kasten FH, Herrmann CS, Witt K, et al. Evidence of Neuroplastic Changes after Transcranial Magnetic, Electric, and Deep Brain Stimulation. Brain Sci. 2022; 12: 929.

[221]

Davidson B, Bhattacharya A, Sarica C, Darmani G, Raies N, Chen R, et al. Neuromodulation techniques - From non-invasive brain stimulation to deep brain stimulation. Neurotherapeutics. 2024; 21: e00330.

[222]

Demirtas-Tatlidede A, Vahabzadeh-Hagh AM, Bernabeu M, Tormos JM, Pascual-Leone A. Noninvasive brain stimulation in traumatic brain injury. J Head Trauma Rehabil. 2012; 27: 274-92.

[223]

Slater C, Liu Y, Weiss E, Yu K, Wang Q. The Neuromodulatory Role of the Noradrenergic and Cholinergic Systems and Their Interplay in Cognitive Functions: A Focused Review. Brain Sci. 2022; 12: 890.

[224]

Hampel H, Mesulam M, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain. 2018; 141: 1917-33.

[225]

Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997; 54: 465-73.

[226]

Paul SM, Yohn SE, Popiolek M, Miller AC, Felder CC. Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia. Am J Psychiatry. 2022; 179: 611-27.

[227]

Singh R, Sadiq NM. Cholinesterase Inhibitors. Treasure Island (FL): StatPearls Publishing; 2025.

[228]

Westbrook A, Braver TS. Dopamine Does Double Duty in Motivating Cognitive Effort. Neuron. 2016; 89: 695-710.

[229]

Avery MC, Krichmar JL. Neuromodulatory Systems and Their Interactions: A Review of Models, Theories, and Experiments. Front Neural Circuits. 2017; 11: 108.

[230]

Miranda M, Morici JF, Zanoni MB, Bekinschtein P. Brain-Derived Neurotrophic Factor: A Key Molecule for Memory in the Healthy and the Pathological Brain. Front Cell Neurosci. 2019; 13: 363.

[231]

Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015; 11: 1164-78.

[232]

Miranda-Lourenço C, Ribeiro-Rodrigues L, Fonseca-Gomes J, Tanqueiro SR, Belo RF, Ferreira CB, et al. Challenges of BDNF-based therapies: From common to rare diseases. Pharmacol Res. 2020; 162: 105281.

[233]

Fonseca-Gomes J, Costa-Coelho T, Ferreira-Manso M, Inteiro-Oliveira S, Vaz SH, Alemãn-Serrano N, et al. A small TAT-TrkB peptide prevents BDNF receptor cleavage and restores synaptic physiology in Alzheimer’s disease. Mol Ther. 2024; 32: 3372-401.

[234]

Tenenbaum L, Humbert-Claude M. Glial Cell Line-Derived Neurotrophic Factor Gene Delivery in Parkinson’s Disease: A Delicate Balance between Neuroprotection, Trophic Effects, and Unwanted Compensatory Mechanisms. Front Neuroanat. 2017; 11: 29.

[235]

Mahato AK, Kopra J, Renko J, Visnapuu T, Korhonen I, Pulkkinen N, et al. Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo. Mov Disord. 2020; 35: 245-55.

[236]

Grondin R, Gash DM. Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson’s disease. J Neurol. 1998; 245: P35-42.

[237]

Xu S, Di Z, He Y, Wang R, Ma Y, Sun R, et al. Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects against Aβ toxicity via attenuating Aβ-induced endoplasmic reticulum stress. J Neuroinflammation. 2019; 16: 35.

[238]

Danilova T, Galli E, Pakarinen E, Palm E, Lindholm P, Saarma M, et al. Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) Is Highly Expressed in Mouse Tissues With Metabolic Function. Front Endocrinol (Lausanne). 2019; 10: 765.

[239]

Mufson EJ, Counts SE, Ginsberg SD, Mahady L, Perez SE, Massa SM, et al. Nerve Growth Factor Pathobiology During the Progression of Alzheimer’s Disease. Front Neurosci. 2019; 13: 533.

[240]

Lioutas V, Alfaro-Martinez F, Bedoya F, Chung C, Pimentel DA, Novak V. Intranasal Insulin and Insulin-Like Growth Factor 1 as Neuroprotectants in Acute Ischemic Stroke. Transl Stroke Res. 2015; 6: 264-75.

[241]

Sil S, Dagur RS, Liao K, Peeples ES, Hu G, Periyasamy P, et al. Strategies for the use of Extracellular Vesicles for the Delivery of Therapeutics. J Neuroimmune Pharmacol. 2020; 15: 422-42.

[242]

Hu N, Chen L, Hu G, Ma R. Advancements in extracellular vesicle therapy for neurodegenerative diseases. Explor Neuroprotective Ther. 2025; 5: 1004104.

[243]

Pañeda A, Collantes M, Beattie SG, Otano I, Snapper J, Timmermans E, et al. Adeno-associated virus liver transduction efficiency measured by in vivo [18F]FHBG positron emission tomography imaging in rodents and nonhuman primates. Hum Gene Ther. 2011; 22: 999-1009.

[244]

Fajardo-Serrano A, Rico AJ, Roda E, Honrubia A, Arrieta S, Ariznabarreta G, et al. Adeno-Associated Viral Vectors as Versatile Tools for Parkinson’s Research, Both for Disease Modeling Purposes and for Therapeutic Uses. Int J Mol Sci. 2021; 22: 6389.

[245]

Nicoló SD, Tarani L, Ceccanti M, Maldini M, Natella F, Vania A, et al. Effects of olive polyphenols administration on nerve growth factor and brain-derived neurotrophic factor in the mouse brain. Nutrition. 2013; 29: 681-7.

[246]

Fiore M, Terracina S, Ferraguti G. Brain Neurotrophins and Plant Polyphenols: A Powerful Connection. Molecules. 2025; 30: 2657.

[247]

Gravesteijn E, Mensink RP, Plat J. Effects of nutritional interventions on BDNF concentrations in humans: a systematic review. Nutr Neurosci. 2022; 25: 1425-36.

[248]

Yeapuri P, Machhi J, Lu Y, Abdelmoaty MM, Kadry R, Patel M, et al. Amyloid-β specific regulatory T cells attenuate Alzheimer’s disease pathobiology in APP/PS1 mice. Mol Neurodegener. 2023; 18: 97.

[249]

Machhi J, Kevadiya BD, Muhammad IK, Herskovitz J, Olson KE, Mosley RL, et al. Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders. Mol Neurodegener. 2020; 15: 32.

[250]

Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease. J Leukoc Biol. 2007; 82: 1083-94.

[251]

Joshi G, Johnson JA. The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases. Recent Pat CNS Drug Discov. 2012; 7: 218-29.

[252]

Dinkova-Kostova AT, Kostov RV, Kazantsev AG. The role of Nrf2 signaling in counteracting neurodegenerative diseases. FEBS J. 2018; 285: 3576-90.

[253]

Nogueiras R, Habegger KM, Chaudhary N, Finan B, Banks AS, Dietrich MO, et al. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev. 2012; 92: 1479-514.

[254]

Wu Q, Zhang T, Chen H, Yu X, Lv J, Liu Y, et al. The sirtuin family in health and disease. Signal Transduct Target Ther. 2022; 7: 402.

[255]

Ungurianu A, Zanfirescu A, Margină D. Sirtuins, resveratrol and the intertwining cellular pathways connecting them. Ageing Res Rev. 2023; 88: 101936.

[256]

Zhao L, Zhao J, Zhong K, Tong A, Jia D. Targeted protein degradation: mechanisms, strategies and application. Signal Transduct Target Ther. 2022; 7: 113.

[257]

Aliper A, Jellen L, Cortese F, Artemov A, Karpinsky-Semper D, Moskalev A, et al. Towards natural mimetics of metformin and rapamycin. Aging (Albany NY). 2017; 9: 2245-68.

[258]

Ma R, Kutchy NA, Hu G. Astrocyte-Derived Extracellular Vesicle-Mediated Activation of Primary Ciliary Signaling Contributes to the Development of Morphine Tolerance. Biol Psychiatry. 2021; 90: 575-85.

[259]

Ma R, Kutchy NA, Chen L, Meigs DD, Hu G. Primary cilia and ciliary signaling pathways in aging and age-related brain disorders. Neurobiol Dis. 2022; 163: 105607.

[260]

Boehlke C, Kotsis F, Patel V, Braeg S, Voelker H, Bredt S, et al. Primary cilia regulate mTORC1 activity and cell size through Lkb1. Nat Cell Biol. 2010; 12: 1115-22.

[261]

Valente EM, Rosti RO, Gibbs E, Gleeson JG. Primary cilia in neurodevelopmental disorders. Nat Rev Neurol. 2014; 10: 27-36.

[262]

Ma R, Chen L, Hu N, Caplan S, Hu G. Cilia and Extracellular Vesicles in Brain Development and Disease. Biol Psychiatry. 2024; 95: 1020-9.

[263]

Ma R, Kutchy NA, Wang Z, Hu G. Extracellular vesicle-mediated delivery of anti-miR-106b inhibits morphine-induced primary ciliogenesis in the brain. Mol Ther. 2023; 31: 1332-45.

[264]

Saito M, Otsu W, Miyadera K, Nishimura Y. Recent advances in the understanding of cilia mechanisms and their applications as therapeutic targets. Front Mol Biosci. 2023; 10: 1232188.

[265]

Schmidt S, Luecken MD, Trümbach D, Hembach S, Niedermeier KM, Wenck N, et al. Primary cilia and SHH signaling impairments in human and mouse models of Parkinson’s disease. Nat Commun. 2022; 13: 4819.

[266]

Volos P, Fujise K, Rafiq NM. Roles for primary cilia in synapses and neurological disorders. Trends Cell Biol. 2025; 35: 6-10.

[267]

Ohtake Y, Hayat U, Li S. PTEN inhibition and axon regeneration and neural repair. Neural Regen Res. 2015; 10: 1363-8.

[268]

O’Donovan KJ. Intrinsic Axonal Growth and the Drive for Regeneration. Front Neurosci. 2016; 10: 486.

[269]

Ribeiro FF, Xapelli S, Miranda-Lourenço C, Tanqueiro SR, Fonseca-Gomes J, Diógenes MJ, et al. Purine nucleosides in neuroregeneration and neuroprotection. Neuropharmacology. 2016; 104: 226-42.

[270]

Solanki N, Dodiya R, Vejpara D, Azad S, Patel M, Patel S, et al. Adenosine receptor subtype modulators: Insight into molecular mechanisms and their therapeutic application. Am J Transl Res. 2025; 17: 2376-95.

[271]

Franco R, Rivas-Santisteban R, Casanovas M, Lillo A, Saura CA, Navarro G. Adenosine A2A Receptor Antagonists Affects NMDA Glutamate Receptor Function. Potential to Address Neurodegeneration in Alzheimer’s Disease. Cells. 2020; 9: 1075.

[272]

Jacobson KA, Pradhan B, Wen Z, Pramanik A. New paradigms in purinergic receptor ligand discovery. Neuropharmacology. 2023; 230: 109503.

[273]

Coppi E, Cherchi F, Venturini M, Lucarini E, Corradetti R, Mannelli LDC, et al. Therapeutic Potential of Highly Selective A3 Adenosine Receptor Ligands in the Central and Peripheral Nervous System. Molecules. 2022; 27: 1890.

[274]

Ghosh A, Ribeiro-Rodrigues L, Ruffolo G, Alfano V, Domingos C, Rei N, et al. Selective modulation of epileptic tissue by an adenosine A3 receptor-activating drug. Br J Pharmacol. 2024; 181: 5041-61.

[275]

Jankowski MP, Cornuet PK, McIlwrath S, Koerber HR, Albers KM. SRY-box containing gene 11 (Sox11) transcription factor is required for neuron survival and neurite growth. Neuroscience. 2006; 143: 501-14.

[276]

Quraishe S, Forbes LH, Andrews MR. The Extracellular Environment of the CNS: Influence on Plasticity, Sprouting, and Axonal Regeneration after Spinal Cord Injury. Neural Plast. 2016; 2016: 2952386.

[277]

Clark IH, Roman A, Fellows E, Radha S, Var SR, Roushdy Z, et al. Cell Reprogramming for Regeneration and Repair of the Nervous System. Biomedicines. 2022; 10: 2598.

[278]

Wang L, Zhang C. In vivo glia-to-neuron conversion: pitfalls and solutions. Dev Neurobiol. 2022; 82: 367-74.

[279]

Galvan A, Caiola MJ, Albaugh DL. Advances in optogenetic and chemogenetic methods to study brain circuits in non-human primates. J Neural Transm (Vienna). 2018; 125: 547-63.

[280]

Franco R, Martínez-Pinilla E, Navarro G, Zamarbide M. Potential of GPCRs to modulate MAPK and mTOR pathways in Alzheimer’s disease. Prog Neurobiol. 2017; 149-150: 21-38.

[281]

Garcia-Lopez P, Garcia-Marin V, Freire M. The histological slides and drawings of Cajal. Front Neuroanat. 2010; 4: 9.

[282]

Escartin C, Galea E, Lakatos A, O’Callaghan JP, Petzold GC, Serrano-Pozo A, et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci. 2021; 24: 312-25.

[283]

Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2003; 74: 1200-5.

[284]

Kim S, Chun H, Kim Y, Kim Y, Park U, Chu J, et al. Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer’s disease. Mol Neurodegener. 2024; 19: 55.

[285]

Ju YH, Bhalla M, Hyeon SJ, Oh JE, Yoo S, Chae U, et al. Astrocytic urea cycle detoxifies Aβ-derived ammonia while impairing memory in Alzheimer’s disease. Cell Metab. 2022; 34: 1104-20.e8.

[286]

Jo S, Yarishkin O, Hwang YJ, Chun YE, Park M, Woo DH, et al. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer’s disease. Nat Med. 2014; 20: 886-96.

[287]

Chun H, Lim J, Park KD, Lee CJ. Inhibition of monoamine oxidase B prevents reactive astrogliosis and scar formation in stab wound injury model. Glia. 2022; 70: 354-67.

[288]

Heo JY, Nam M, Yoon HH, Kim J, Hwang YJ, Won W, et al. Aberrant Tonic Inhibition of Dopaminergic Neuronal Activity Causes Motor Symptoms in Animal Models of Parkinson’s Disease. Curr Biol. 2020; 30: 276-91.e9.

[289]

Nam M, Cho J, Kwon D, Park J, Woo J, Lee JM, et al. Excessive Astrocytic GABA Causes Cortical Hypometabolism and Impedes Functional Recovery after Subcortical Stroke. Cell Rep. 2020; 32: 107861.

[290]

Nam M, Park J, Song HJ, Choi JW, Kim S, Jang BK, et al. KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson’s Disease. Neurotherapeutics. 2021; 18: 1729-47.

[291]

Zeisel A, Hochgerner H, Lönnerberg P, Johnsson A, Memic F, van der Zwan J, et al. Molecular Architecture of the Mouse Nervous System. Cell. 2018; 174: 999-1014.e22.

[292]

Verhoog QP, Holtman L, Aronica E, van Vliet EA. Astrocytes as Guardians of Neuronal Excitability: Mechanisms Underlying Epileptogenesis. Front Neurol. 2020; 11: 591690.

[293]

Hatten ME, Liem RK, Shelanski ML, Mason CA. Astroglia in CNS injury. Glia. 1991; 4: 233-43.

[294]

Haidet-Phillips AM, Hester ME, Miranda CJ, Meyer K, Braun L, Frakes A, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol. 2011; 29: 824-8.

[295]

Alberini CM, Cruz E, Descalzi G, Bessières B, Gao V. Astrocyte glycogen and lactate: New insights into learning and memory mechanisms. Glia. 2018; 66: 1244-62.

[296]

Bélanger M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab. 2011; 14: 724-38.

[297]

Yao S, Xu M, Wang Y, Zhao S, Wang J, Chen G, et al. Astrocytic lactate dehydrogenase A regulates neuronal excitability and depressive-like behaviors through lactate homeostasis in mice. Nat Commun. 2023; 14: 729.

[298]

Horvat A, Zorec R, Vardjan N. Lactate as an Astroglial Signal Augmenting Aerobic Glycolysis and Lipid Metabolism. Front Physiol. 2021; 12: 735532.

[299]

Lee S, Yoon B, Berglund K, Oh S, Park H, Shin H, et al. Channel-mediated tonic GABA release from glia. Science. 2010; 330: 790-6.

[300]

Yoon B, Woo J, Chun Y, Chun H, Jo S, Bae JY, et al. Glial GABA, synthesized by monoamine oxidase B, mediates tonic inhibition. J Physiol. 2014; 592: 4951-68.

[301]

Kwak H, Koh W, Kim S, Song K, Shin J, Lee JM, et al. Astrocytes Control Sensory Acuity via Tonic Inhibition in the Thalamus. Neuron. 2020; 108: 691-706.e10.

[302]

Koh W, Kwak H, Cheong E, Lee CJ. GABA tone regulation and its cognitive functions in the brain. Nat Rev Neurosci. 2023; 24: 523-39.

[303]

Oh S, Han K, Park H, Woo DH, Kim HY, Traynelis SF, et al. Protease activated receptor 1-induced glutamate release in cultured astrocytes is mediated by Bestrophin-1 channel but not by vesicular exocytosis. Mol Brain. 2012; 5: 38.

[304]

Yang J, Chen J, Liu Y, Chen KH, Baraban JM, Qiu Z. Ventral tegmental area astrocytes modulate cocaine reward by tonically releasing GABA. Neuron. 2023; 111: 1104-17.e6.

[305]

Bhalla M, Joo J, Kim D, Shin JI, Park YM, Ju YH, et al. SIRT2 and ALDH1A1 as critical enzymes for astrocytic GABA production in Alzheimer’s disease. Mol Neurodegener. 2025; 20: 6.

[306]

Koh W, Park M, Chun YE, Lee J, Shim HS, Park MG, et al. Astrocytes Render Memory Flexible by Releasing D-Serine and Regulating NMDA Receptor Tone in the Hippocampus. Biol Psychiatry. 2022; 91: 740-52.

[307]

Furukawa H, Singh SK, Mancusso R, Gouaux E. Subunit arrangement and function in NMDA receptors. Nature. 2005; 438: 185-92.

[308]

Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron. 1996; 16: 675-86.

[309]

Fleming TM, Scott V, Naskar K, Joe N, Brown CH, Stern JE. State-dependent changes in astrocyte regulation of extrasynaptic NMDA receptor signalling in neurosecretory neurons. J Physiol. 2011; 589: 3929-41.

[310]

Valtcheva S, Venance L. Control of Long-Term Plasticity by Glutamate Transporters. Front Synaptic Neurosci. 2019; 11: 10.

[311]

Nam M, Han K, Lee J, Bae JY, An H, Park S, et al. Expression of µ-Opioid Receptor in CA1 Hippocampal Astrocytes. Exp Neurobiol. 2018; 27: 120-8.

[312]

Schousboe A. Astrocytic Metabolism Focusing on Glutamate Homeostasis: A Short Review Dedicated to Vittorio Gallo. Neurochem Res. 2020; 45: 522-5.

[313]

Rose CF, Verkhratsky A, Parpura V. Astrocyte glutamine synthetase: pivotal in health and disease. Biochem Soc Trans. 2013; 41: 1518-24.

[314]

Rae C, Moussa CE, Griffin JL, Parekh SB, Bubb WA, Hunt NH, et al. A metabolomic approach to ionotropic glutamate receptor subtype function: a nuclear magnetic resonance in vitro investigation. J Cereb Blood Flow Metab. 2006; 26: 1005-17.

[315]

Krishnan KS, Billups B. ASC Transporters Mediate D-Serine Transport into Astrocytes Adjacent to Synapses in the Mouse Brain. Biomolecules. 2023; 13: 819.

[316]

Mothet J, Pollegioni L, Ouanounou G, Martineau M, Fossier P, Baux G. Glutamate receptor activation triggers a calcium-dependent and SNARE protein-dependent release of the gliotransmitter D-serine. Proc Natl Acad Sci U S A. 2005; 102: 5606-11.

[317]

Shigetomi E, Jackson-Weaver O, Huckstepp RT, O’Dell TJ, Khakh BS. TRPA1 channels are regulators of astrocyte basal calcium levels and long-term potentiation via constitutive D-serine release. J Neurosci. 2013; 33: 10143-53.

[318]

Henneberger C, Papouin T, Oliet SHR, Rusakov DA. Long-term potentiation depends on release of D-serine from astrocytes. Nature. 2010; 463: 232-6.

[319]

Bergersen LH, Morland C, Ormel L, Rinholm JE, Larsson M, Wold JFH, et al. Immunogold detection of L-glutamate and D-serine in small synaptic-like microvesicles in adult hippocampal astrocytes. Cereb Cortex. 2012; 22: 1690-7.

[320]

Orzylowski M, Fujiwara E, Mousseau DD, Baker GB. An Overview of the Involvement of D-Serine in Cognitive Impairment in Normal Aging and Dementia. Front Psychiatry. 2021; 12: 754032.

[321]

Durkee C, Kofuji P, Navarrete M, Araque A. Astrocyte and neuron cooperation in long-term depression. Trends Neurosci. 2021; 44: 837-48.

[322]

Tan Z, Liu Y, Xi W, Lou H, Zhu L, Guo Z, et al. Glia-derived ATP inversely regulates excitability of pyramidal and CCK-positive neurons. Nat Commun. 2017; 8: 13772.

[323]

Gomes JI, Farinha-Ferreira M, Rei N, Gonçalves-Ribeiro J, Ribeiro JA, Sebastião AM, et al. Of adenosine and the blues: The adenosinergic system in the pathophysiology and treatment of major depressive disorder. Pharmacol Res. 2021; 163: 105363.

[324]

Lee J, Chun Y, Han K, Lee J, Woo DH, Lee CJ. Ca(2+) Entry is Required for Mechanical Stimulation-induced ATP Release from Astrocyte. Exp Neurobiol. 2015;24:17-23.

[325]

Xiong Y, Sun S, Teng S, Jin M, Zhou Z. Ca2+-Dependent and Ca2+-Independent ATP Release in Astrocytes. Front Mol Neurosci. 2018; 11: 224.

[326]

Lezmy J. How astrocytic ATP shapes neuronal activity and brain circuits. Curr Opin Neurobiol. 2023; 79: 102685.

[327]

Latini S, Pedata F. Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem. 2001; 79: 463-84.

[328]

Mendonça Ad, Sebastião AM, Ribeiro JA. Inhibition of NMDA receptor-mediated currents in isolated rat hippocampal neurones by adenosine A1 receptor activation. Neuroreport. 1995; 6: 1097-100.

[329]

Cunha RA, Ribeiro JA. Purinergic modulation of [(3)H]GABA release from rat hippocampal nerve terminals. Neuropharmacology. 2000; 39: 1156-67.

[330]

Matos M, Bosson A, Riebe I, Reynell C, Vallée J, Laplante I, et al. Astrocytes detect and upregulate transmission at inhibitory synapses of somatostatin interneurons onto pyramidal cells. Nat Commun. 2018; 9: 4254.

[331]

Puerto AD, Fronzaroli-Molinieres L, Perez-Alvarez MJ, Giraud P, Carlier E, Wandosell F, et al. ATP-P2X7 Receptor Modulates Axon Initial Segment Composition and Function in Physiological Conditions and Brain Injury. Cereb Cortex. 2015; 25: 2282-94.

[332]

Chen N, Sugihara H, Sharma J, Perea G, Petravicz J, Le C, et al. Nucleus basalis-enabled stimulus-specific plasticity in the visual cortex is mediated by astrocytes. Proc Natl Acad Sci U S A. 2012; 109: E2832-41.

[333]

Covelo A, Araque A. Neuronal activity determines distinct gliotransmitter release from a single astrocyte. Elife. 2018; 7: e32237.

[334]

Pascual O, Casper KB, Kubera C, Zhang J, Revilla-Sanchez R, Sul J, et al. Astrocytic purinergic signaling coordinates synaptic networks. Science. 2005; 310: 113-6.

[335]

Pérez-Rodríguez M, Arroyo-García LE, Prius-Mengual J, Andrade-Talavera Y, Armengol JA, Pérez-Villegas EM, et al. Adenosine Receptor-Mediated Developmental Loss of Spike Timing-Dependent Depression in the Hippocampus. Cereb Cortex. 2019; 29: 3266-81.

[336]

Serrano A, Haddjeri N, Lacaille J, Robitaille R. GABAergic network activation of glial cells underlies hippocampal heterosynaptic depression. J Neurosci. 2006; 26: 5370-82.

[337]

Zhang J, Wang H, Ye C, Ge W, Chen Y, Jiang Z, et al. ATP released by astrocytes mediates glutamatergic activity-dependent heterosynaptic suppression. Neuron. 2003; 40: 971-82.

[338]

Halassa MM, Florian C, Fellin T, Munoz JR, Lee S, Abel T, et al. Astrocytic modulation of sleep homeostasis and cognitive consequences of sleep loss. Neuron. 2009; 61: 213-9.

[339]

Brockhaus J, Deitmer JW. Long-lasting modulation of synaptic input to Purkinje neurons by Bergmann glia stimulation in rat brain slices. J Physiol. 2002; 545: 581-93.

[340]

Newman EA. Propagation of intercellular calcium waves in retinal astrocytes and Müller cells. J Neurosci. 2001; 21: 2215-23.

[341]

Martin-Fernandez M, Jamison S, Robin LM, Zhao Z, Martin ED, Aguilar J, et al. Synapse-specific astrocyte gating of amygdala-related behavior. Nat Neurosci. 2017; 20: 1540-8.

[342]

Corkrum M, Rothwell PE, Thomas MJ, Kofuji P, Araque A. Opioid-Mediated Astrocyte-Neuron Signaling in the Nucleus Accumbens. Cells. 2019; 8: 586.

[343]

Panatier A, Vallée J, Haber M, Murai KK, Lacaille J, Robitaille R. Astrocytes are endogenous regulators of basal transmission at central synapses. Cell. 2011; 146: 785-98.

[344]

Rombo DM, Newton K, Nissen W, Badurek S, Horn JM, Minichiello L, et al. Synaptic mechanisms of adenosine A2A receptor-mediated hyperexcitability in the hippocampus. Hippocampus. 2015; 25: 566-80.

[345]

Wang M, Li P, Li Z, da Silva BS, Zheng W, Xiang Z, et al. Lateral septum adenosine A2A receptors control stress-induced depressive-like behaviors via signaling to the hypothalamus and habenula. Nat Commun. 2023; 14: 1880.

[346]

Chun H, An H, Lim J, Woo J, Lee J, Ryu H, et al. Astrocytic proBDNF and Tonic GABA Distinguish Active versus Reactive Astrocytes in Hippocampus. Exp Neurobiol. 2018; 27: 155-70.

[347]

Vignoli B, Battistini G, Melani R, Blum R, Santi S, Berardi N, et al. Peri-Synaptic Glia Recycles Brain-Derived Neurotrophic Factor for LTP Stabilization and Memory Retention. Neuron. 2016; 92: 873-87.

[348]

Chun H, Lee CJ. Reactive astrocytes in Alzheimer’s disease: A double-edged sword. Neurosci Res. 2018; 126: 44-52.

[349]

Albini M, Krawczun-Rygmaczewska A, Cesca F. Astrocytes and brain-derived neurotrophic factor (BDNF). Neurosci Res. 2023; 197: 42-51.

[350]

Han J, Yoon S, Park H. Endocytic BDNF secretion regulated by Vamp3 in astrocytes. Sci Rep. 2021; 11: 21203.

[351]

Rose CR, Blum R, Pichler B, Lepier A, Kafitz KW, Konnerth A. Truncated TrkB-T1 mediates neurotrophin-evoked calcium signalling in glia cells. Nature. 2003; 426: 74-8.

[352]

Vaz SH, Jørgensen TN, Cristóvão-Ferreira S, Duflot S, Ribeiro JA, Gether U, et al. Brain-derived neurotrophic factor (BDNF) enhances GABA transport by modulating the trafficking of GABA transporter-1 (GAT-1) from the plasma membrane of rat cortical astrocytes. J Biol Chem. 2011; 286: 40464-76.

[353]

Hartmann M, Brigadski T, Erdmann KS, Holtmann B, Sendtner M, Narz F, et al. Truncated TrkB receptor-induced outgrowth of dendritic filopodia involves the p75 neurotrophin receptor. J Cell Sci. 2004; 117: 5803-14.

[354]

Ohira K, Funatsu N, Homma KJ, Sahara Y, Hayashi M, Kaneko T, et al. Truncated TrkB-T1 regulates the morphology of neocortical layer I astrocytes in adult rat brain slices. Eur J Neurosci. 2007; 25: 406-16.

[355]

Ohira K, Kumanogoh H, Sahara Y, Homma KJ, Hirai H, Nakamura S, et al. A truncated tropomyosin-related kinase B receptor, T1, regulates glial cell morphology via Rho GDP dissociation inhibitor 1. J Neurosci. 2005; 25: 1343-53.

[356]

Lu Y, Jiang B, Cao D, Zhang Z, Zhang X, Ji R, et al. TRAF6 upregulation in spinal astrocytes maintains neuropathic pain by integrating TNF-α and IL-1β signaling. Pain. 2014; 155: 2618-29.

[357]

Giovannoni F, Quintana FJ. The Role of Astrocytes in CNS Inflammation. Trends Immunol. 2020; 41: 805-19.

[358]

Linnerbauer M, Wheeler MA, Quintana FJ. Astrocyte Crosstalk in CNS Inflammation. Neuron. 2020; 108: 608-22.

[359]

Chen Y, Qin C, Huang J, Tang X, Liu C, Huang K, et al. The role of astrocytes in oxidative stress of central nervous system: A mixed blessing. Cell Prolif. 2020; 53: e12781.

[360]

Chun H, Im H, Kang YJ, Kim Y, Shin JH, Won W, et al. Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer’s disease via H2O2 production. Nat Neurosci. 2020; 23: 1555-66.

[361]

Won W, Lee EH, Gotina L, Chun H, Lee JH, Park U, et al. Hemoglobin as a peroxidase and drug target for oxidative stress-related diseases. BioRxiv 594979 [Preprint]. 2024 [cited 2025 Dec 10]. Available from: https://www.biorxiv.org/content/10.1101/2024.05.21.594979v2

[362]

Yamamoto S, Wajima T, Hara Y, Nishida M, Mori Y. Transient receptor potential channels in Alzheimer’s disease. Biochim Biophys Acta. 2007; 1772: 958-67.

[363]

Lee SH, Lee M, Ko DG, Choi BY, Suh SW. The Role of NADPH Oxidase in Neuronal Death and Neurogenesis after Acute Neurological Disorders. Antioxidants (Basel). 2021; 10: 739.

[364]

Kleinert H, Schwarz PM, Förstermann U. Regulation of the expression of inducible nitric oxide synthase. Biol Chem. 2003; 384: 1343-64.

[365]

Ansari MA, Scheff SW. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol. 2010; 69: 155-67.

[366]

Bi C, Tham DKL, Perronnet C, Joshi B, Nabi IR, Moukhles H. The Oxidative Stress-Induced Increase in the Membrane Expression of the Water-Permeable Channel Aquaporin-4 in Astrocytes Is Regulated by Caveolin-1 Phosphorylation. Front Cell Neurosci. 2017; 11: 412.

[367]

Arnaiz SL, D’Amico G, Paglia N, Arismendi M, Basso N, del Rosario Lores Arnaiz M. Enriched environment, nitric oxide production and synaptic plasticity prevent the aging-dependent impairment of spatial cognition. Mol Aspects Med. 2004; 25: 91-101.

[368]

Liu R, Wang J, Chen Y, Collier JM, Capuk O, Jin S, et al. NOX activation in reactive astrocytes regulates astrocytic LCN2 expression and neurodegeneration. Cell Death Dis. 2022; 13: 371.

[369]

Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001; 65: 1-105.

[370]

Armada-Moreira A, Gomes JI, Pina CC, Savchak OK, Gonçalves-Ribeiro J, Rei N, et al. Going the Extra (Synaptic) Mile: Excitotoxicity as the Road Toward Neurodegenerative Diseases. Front Cell Neurosci. 2020; 14: 90.

[371]

Herman MA, Jahr CE. Extracellular glutamate concentration in hippocampal slice. J Neurosci. 2007; 27: 9736-41.

[372]

Gonçalves-Ribeiro J, Pina CC, Sebastião AM, Vaz SH. Glutamate Transporters in Hippocampal LTD/LTP: Not Just Prevention of Excitotoxicity. Front Cell Neurosci. 2019; 13: 357.

[373]

Danbolt NC, Furness DN, Zhou Y. Neuronal vs glial glutamate uptake: Resolving the conundrum. Neurochem Int. 2016; 98: 29-45.

[374]

Jacob CP, Koutsilieri E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N, et al. Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer’s disease. J Alzheimers Dis. 2007; 11: 97-116.

[375]

Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease. Neurochem Int. 2004; 45: 583-95.

[376]

Talantova M, Sanz-Blasco S, Zhang X, Xia P, Akhtar MW, Okamoto S, et al. Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A. 2013; 110: E2518-27.

[377]

Howland DS, Liu J, She Y, Goad B, Maragakis NJ, Kim B, et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci U S A. 2002; 99: 1604-9.

[378]

Pardo AC, Wong V, Benson LM, Dykes M, Tanaka K, Rothstein JD, et al. Loss of the astrocyte glutamate transporter GLT1 modifies disease in SOD1(G93A) mice. Exp Neurol. 2006; 201: 120-30.

[379]

Dunlop J, McIlvain HB, She Y, Howland DS. Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. J Neurosci. 2003; 23: 1688-96.

[380]

Costa-Pinto S, Gonçalves-Ribeiro J, Tedim-Moreira J, Socodato R, Relvas JB, Sebastião AM, et al. Communication defects with astroglia contribute to early impairments in the motor cortex plasticity of SOD1G93Amice. Neurobiol Dis. 2024;193:106435.

[381]

Lin CL, Bristol LA, Jin L, Dykes-Hoberg M, Crawford T, Clawson L, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron. 1998; 20: 589-602.

[382]

Maragakis NJ, Dykes-Hoberg M, Rothstein JD. Altered expression of the glutamate transporter EAAT2b in neurological disease. Ann Neurol. 2004; 55: 469-77.

[383]

Boycott HE, Wilkinson JA, Boyle JP, Pearson HA, Peers C. Differential involvement of TNF alpha in hypoxic suppression of astrocyte glutamate transporters. Glia. 2008; 56: 998-1004.

[384]

Jiang L, Zhu B, Zhao Y, Li X, Liu T, Pina-Crespo J, et al. Membralin deficiency dysregulates astrocytic glutamate homeostasis leading to ALS-like impairment. J Clin Invest. 2019; 129: 3103-20.

[385]

Emdad L, Sarkar D, Su Z, Lee S, Kang D, Bruce JN, et al. Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration. Pharmacol Ther. 2007; 114: 155-70.

[386]

Gibb SL, Boston-Howes W, Lavina ZS, Gustincich S, Brown RH Jr, Pasinelli P, et al. A caspase-3-cleaved fragment of the glial glutamate transporter EAAT2 is sumoylated and targeted to promyelocytic leukemia nuclear bodies in mutant SOD1-linked amyotrophic lateral sclerosis. J Biol Chem. 2007; 282: 32480-90.

[387]

Rosenblum LT, Shamamandri-Markandaiah S, Ghosh B, Foran E, Lepore AC, Pasinelli P, et al. Mutation of the caspase-3 cleavage site in the astroglial glutamate transporter EAAT2 delays disease progression and extends lifespan in the SOD1-G93A mouse model of ALS. Exp Neurol. 2017; 292: 145-53.

[388]

Hoye ML, Koval ED, Wegener AJ, Hyman TS, Yang C, O’Brien DR, et al. MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models. J Neurosci. 2017; 37: 5574-86.

[389]

Hoye ML, Regan MR, Jensen LA, Lake AM, Reddy LV, Vidensky S, et al. Motor neuron-derived microRNAs cause astrocyte dysfunction in amyotrophic lateral sclerosis. Brain. 2018; 141: 2561-75.

[390]

Morel L, Regan M, Higashimori H, Ng SK, Esau C, Vidensky S, et al. Neuronal exosomal miRNA-dependent translational regulation of astroglial glutamate transporter GLT1. J Biol Chem. 2013; 288: 7105-16.

[391]

Sugiyama K, Tanaka K. Spinal cord-specific deletion of the glutamate transporter GLT1 causes motor neuron death in mice. Biochem Biophys Res Commun. 2018; 497: 689-93.

[392]

Guo H, Lai L, Butchbach MER, Stockinger MP, Shan X, Bishop GA, et al. Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum Mol Genet. 2003; 12: 2519-32.

[393]

Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005; 433: 73-7.

[394]

Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, et al.; Ceftriaxone Study Investigators. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014; 13: 1083-91.

[395]

Rothstein JD. Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials. Ann Neurol. 2003; 53: 423-6.

[396]

Beghi E, Bendotti C, Mennini T. New ideas for therapy in ALS: critical considerations. Amyotroph Lateral Scler. 2006; 7: 126-7.

[397]

García O, Massieu L. Glutamate uptake inhibitor L-trans-pyrrolidine 2,4-dicarboxylate becomes neurotoxic in the presence of subthreshold concentrations of mitochondrial toxin 3-nitropropionate: involvement of mitochondrial reducing activity and ATP production. J Neurosci Res. 2003; 74: 956-66.

[398]

Silva SD, Turner BJ, Perera ND. Metabolic Dysfunction in Motor Neuron Disease: Shedding Light through the Lens of Autophagy. Metabolites. 2022; 12: 574.

[399]

Moussa CE, Rae C, Bubb WA, Griffin JL, Deters NA, Balcar VJ. Inhibitors of glutamate transport modulate distinct patterns in brain metabolism. J Neurosci Res. 2007; 85: 342-50.

[400]

Colton CK, Kong Q, Lai L, Zhu MX, Seyb KI, Cuny GD, et al. Identification of translational activators of glial glutamate transporter EAAT2 through cell-based high-throughput screening: an approach to prevent excitotoxicity. J Biomol Screen. 2010; 15: 653-62.

[401]

Kong Q, Chang L, Takahashi K, Liu Q, Schulte DA, Lai L, et al. Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection. J Clin Invest. 2014; 124: 1255-67.

[402]

Wilkie CM, Barron JC, Brymer KJ, Barnes JR, Nafar F, Parsons MP. The Effect of GLT-1 Upregulation on Extracellular Glutamate Dynamics. Front Cell Neurosci. 2021; 15: 661412.

[403]

Benkler C, Barhum Y, Ben-Zur T, Offen D. Multifactorial Gene Therapy Enhancing the Glutamate Uptake System and Reducing Oxidative Stress Delays Symptom Onset and Prolongs Survival in the SOD1-G93A ALS Mouse Model. J Mol Neurosci. 2016; 58: 46-58.

[404]

Camassa LMA, Lunde LK, Hoddevik EH, Stensland M, Boldt HB, Souza GAD, et al. Mechanisms underlying AQP4 accumulation in astrocyte endfeet. Glia. 2015; 63: 2073-91.

[405]

Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med. 2012; 4: 147ra111.

[406]

Xu Z, Xiao N, Chen Y, Huang H, Marshall C, Gao J, et al. Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Aβ accumulation and memory deficits. Mol Neurodegener. 2015; 10: 58.

[407]

Yang J, Lunde LK, Nuntagij P, Oguchi T, Camassa LMA, Nilsson LNG, et al. Loss of astrocyte polarization in the tg-ArcSwe mouse model of Alzheimer’s disease. J Alzheimers Dis. 2011; 27: 711-22.

[408]

Kress BT, Iliff JJ, Xia M, Wang M, Wei HS, Zeppenfeld D, et al. Impairment of paravascular clearance pathways in the aging brain. Ann Neurol. 2014; 76: 845-61.

[409]

Moftakhar P, Lynch MD, Pomakian JL, Vinters HV. Aquaporin expression in the brains of patients with or without cerebral amyloid angiopathy. J Neuropathol Exp Neurol. 2010; 69: 1201-9.

[410]

Harrison IF, Ismail O, Machhada A, Colgan N, Ohene Y, Nahavandi P, et al. Impaired glymphatic function and clearance of tau in an Alzheimer's disease model. Brain. 2020; 143: 2576-93.

[411]

Das A, Wallace GC 4th, Holmes C, McDowell ML, Smith JA, Marshall JD, et al. Hippocampal tissue of patients with refractory temporal lobe epilepsy is associated with astrocyte activation, inflammation, and altered expression of channels and receptors. Neuroscience. 2012; 220: 237-46.

[412]

Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV. Establishment and Dysfunction of the Blood-Brain Barrier. Cell. 2015; 163: 1064-78.

[413]

Vasciaveo V, Iadarola A, Casile A, Dante D, Morello G, Minotta L, et al. Sleep fragmentation affects glymphatic system through the different expression of AQP4 in wild type and 5xFAD mouse models. Acta Neuropathol Commun. 2023; 11: 16.

[414]

Silva I, Silva J, Ferreira R, Trigo D. Glymphatic system, AQP4, and their implications in Alzheimer’s disease. Neurol Res Pract. 2021; 3: 5.

[415]

Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005; 202: 473-7.

[416]

Pisani F, Mola MG, Simone L, Rosito S, Alberga D, Mangiatordi GF, et al. Identification of a point mutation impairing the binding between aquaporin-4 and neuromyelitis optica autoantibodies. J Biol Chem. 2014; 289: 30578-89.

[417]

Illarionova NB, Gunnarson E, Li Y, Brismar H, Bondar A, Zelenin S, et al. Functional and molecular interactions between aquaporins and Na,K-ATPase. Neuroscience. 2010; 168: 915-25.

[418]

Yao D, Li R, Hao J, Huang H, Wang X, Ran L, et al. Melatonin alleviates depression-like behaviors and cognitive dysfunction in mice by regulating the circadian rhythm of AQP4 polarization. Transl Psychiatry. 2023; 13: 310.

[419]

Duan T, Tradtrantip L, Phuan P, Bennett JL, Verkman AS. Affinity-matured ‘aquaporumab’ anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders. Neuropharmacology. 2020; 162: 107827.

[420]

Rane Levendovszky S, Flores J, Peskind ER, Václavů L, van Osch MJ, Iliff J. Preliminary investigations into human neurofluid transport using multiple novel non-contrast MRI methods. J Cereb Blood Flow Metab. 2024; 44: 1580-92.

[421]

Illes P. P2X7 Receptors Amplify CNS Damage in Neurodegenerative Diseases. Int J Mol Sci. 2020; 21: 5996.

[422]

Lee J, Ryu H, Ferrante RJ, Morris SM Jr, Ratan RR. Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc Natl Acad Sci U S A. 2003; 100: 4843-8.

[423]

Dias L, Nabais AM, Borges-Martins VPP, Canas PM, Cunha RA, Agostinho P. Impact of Glucocorticoid-Associated Stress-Like Conditions on Aquaporin-4 in Cultured Astrocytes and Its Modulation by Adenosine A2A Receptors. J Neurochem. 2025; 169: e16299.

[424]

Nikolic L, Nobili P, Shen W, Audinat E. Role of astrocyte purinergic signaling in epilepsy. Glia. 2020; 68: 1677-91.

[425]

Álvarez-Ferradas C, Morales JC, Wellmann M, Nualart F, Roncagliolo M, Fuenzalida M, et al. Enhanced astroglial Ca2+signaling increases excitatory synaptic strength in the epileptic brain. Glia. 2015; 63: 1507-21.

[426]

Nikolic L, Shen W, Nobili P, Virenque A, Ulmann L, Audinat E. Blocking TNFα-driven astrocyte purinergic signaling restores normal synaptic activity during epileptogenesis. Glia. 2018; 66: 2673-83.

[427]

Amadio S, Parisi C, Piras E, Fabbrizio P, Apolloni S, Montilli C, et al. Modulation of P2X7 Receptor during Inflammation in Multiple Sclerosis. Front Immunol. 2017; 8: 1529.

[428]

Amadio S, Montilli C, Picconi B, Calabresi P, Volonté C. Mapping P2X and P2Y receptor proteins in striatum and substantia nigra: An immunohistological study. Purinergic Signal. 2007; 3: 389-98.

[429]

Bijelić DD, Milićević KD, Lazarević MN, Miljković DM, Pristov JJB, Savić DZ, et al. Central nervous system-infiltrated immune cells induce calcium increase in astrocytes via astroglial purinergic signaling. J Neurosci Res. 2020; 98: 2317-32.

[430]

Grygorowicz T, Wełniak-Kamińska M, Strużyńska L. Early P2X7R-related astrogliosis in autoimmune encephalomyelitis. Mol Cell Neurosci. 2016; 74: 1-9.

[431]

Yoshida Y, Une F, Utatsu Y, Nomoto M, Furukawa Y, Maruyama Y, et al. Adenosine and neopterin levels in cerebrospinal fluid of patients with neurological disorders. Intern Med. 1999; 38: 133-9.

[432]

Vincenzi F, Corciulo C, Targa M, Casetta I, Gentile M, Granieri E, et al. A2A adenosine receptors are up-regulated in lymphocytes from amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14: 406-13.

[433]

Rei N, Valente CA, Vaz SH, Farinha-Ferreira M, Ribeiro JA, Sebastião AM. Changes in adenosine receptors and neurotrophic factors in the SOD1G93A mouse model of amyotrophic lateral sclerosis: Modulation by chronic caffeine. PLoS One. 2022; 17: e0272104.

[434]

Rei N, Rombo DM, Ferreira MF, Baqi Y, Müller CE, Ribeiro JA, et al. Hippocampal synaptic dysfunction in the SOD1G93Amouse model of Amyotrophic Lateral Sclerosis: Reversal by adenosine A2AR blockade. Neuropharmacology. 2020; 171: 108106.

[435]

Vaz SH, Pinto S, Sebastião AM, Brites D. Astrocytes in Amyotrophic Lateral Sclerosis. In: Araki T, editor. Amyotrophic Lateral Sclerosis. Brisbane (AU): Exon Publications; 2021.

[436]

Rasmussen MK, Mestre H, Nedergaard M. The glymphatic pathway in neurological disorders. Lancet Neurol. 2018; 17: 1016-24.

[437]

Mogensen FL, Delle C, Nedergaard M. The Glymphatic System (En)during Inflammation. Int J Mol Sci. 2021; 22: 7491.

[438]

Hou X, Li Y, Huang Y, Zhao H, Gui L. Adenosine Receptor A1-A2a Heteromers Regulate EAAT2 Expression and Glutamate Uptake via YY1-Induced Repression of PPAR γ Transcription. PPAR Res. 2016; 2016: 2410264.

[439]

Sierra A, de Castro F, Del Río-Hortega J, Rafael Iglesias-Rozas J, Garrosa M, Kettenmann H. The “Big-Bang” for modern glial biology: Translation and comments on Pío del Río-Hortega 1919 series of papers on microglia. Glia. 2016; 64: 1801-40.

[440]

Del Rio-Hortega P. Studies on neuroglia: Glia with very few processes (oligodendroglia) by PÃ-o del RÃ-o-Hortega. 1921. Clin Neuropathol. 2012; 31: 440-59.

[441]

Boullerne AI, Feinstein DL. History of Neuroscience I. Pío del Río-Hortega (1882-1945): The Discoverer of Microglia and Oligodendroglia. ASN Neuro. 2020; 12: 1759091420953259.

[442]

Shabab T, Khanabdali R, Moghadamtousi SZ, Kadir HA, Mohan G. Neuroinflammation pathways: a general review. Int J Neurosci. 2017; 127: 624-33.

[443]

Li Y, Chen X, Zhou M, Feng S, Peng X, Wang Y. Microglial TLR4/NLRP3 Inflammasome Signaling in Alzheimer’s Disease. J Alzheimers Dis. 2024; 97: 75-88.

[444]

Zhou Y, Chen Y, Xu C, Zhang H, Lin C. TLR4 Targeting as a Promising Therapeutic Strategy for Alzheimer Disease Treatment. Front Neurosci. 2020; 14: 602508.

[445]

Jha NK, Jha SK, Kar R, Nand P, Swati K, Goswami VK. Nuclear factor-kappa β as a therapeutic target for Alzheimer’s disease. J Neurochem. 2019; 150: 113-37.

[446]

Dutta D, Jana M, Majumder M, Mondal S, Roy A, Pahan K. Selective targeting of the TLR2/MyD88/NF-κB pathway reduces α-synuclein spreading in vitro and in vivo. Nat Commun. 2021; 12: 5382.

[447]

Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. Nat Med. 2020; 26: 131-42.

[448]

Qin Q, Teng Z, Liu C, Li Q, Yin Y, Tang Y. TREM2, microglia, and Alzheimer’s disease. Mech Ageing Dev. 2021; 195: 111438.

[449]

Wang S, Sudan R, Peng V, Zhou Y, Du S, Yuede CM, et al. TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways. Cell. 2022; 185: 4153-69.e19.

[450]

Zhao Y, Wu X, Li X, Jiang L, Gui X, Liu Y, et al. TREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function. Neuron. 2018; 97: 1023-31.e7.

[451]

Heneka MT, McManus RM, Latz E. Inflammasome signalling in brain function and neurodegenerative disease. Nat Rev Neurosci. 2018; 19: 610-21.

[452]

Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019; 575: 669-73.

[453]

Heneka MT, Carson MJ, Khoury JE, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015; 14: 388-405.

[454]

Perry VH, Teeling J. Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration. Semin Immunopathol. 2013; 35: 601-12.

[455]

Block ML, Hong J. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol. 2005; 76: 77-98.

[456]

Sierra A, Beccari S, Diaz-Aparicio I, Encinas JM, Comeau S, Tremblay M. Surveillance, phagocytosis, and inflammation: how never-resting microglia influence adult hippocampal neurogenesis. Neural Plast. 2016; 2016: 610343.

[457]

Rodriguez-Pallares J, Parga JA, Muñoz A, Rey P, Guerra MJ, Labandeira-Garcia JL. Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. J Neurochem. 2007; 103: 145-56.

[458]

Rodriguez-Perez AI, Borrajo A, Rodriguez-Pallares J, Guerra MJ, Labandeira-Garcia JL. Interaction between NADPH-oxidase and Rho-kinase in angiotensin II-induced microglial activation. Glia. 2015; 63: 466-82.

[459]

Fernández-Suárez D, Celorrio M, Riezu-Boj JI, Ugarte A, Pacheco R, González H, et al. Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. Neurobiol Aging. 2014; 35: 2603-16.

[460]

Edison P, Ahmed I, Fan Z, Hinz R, Gelosa G, Chaudhuri KR, et al. Microglia, amyloid, and glucose metabolism in Parkinson’s disease with and without dementia. Neuropsychopharmacology. 2013; 38: 938-49.

[461]

Cumming P, Borghammer P. Molecular imaging and the neuropathologies of Parkinson's disease. Curr Top Behav Neurosci. 2012; 11: 117-48.

[462]

Lavisse S, Goutal S, Wimberley C, Tonietto M, Bottlaender M, Gervais P, et al. Increased microglial activation in patients with Parkinson disease using [18F]-DPA714 TSPO PET imaging. Parkinsonism Relat Disord. 2021; 82: 29-36.

[463]

Politis M, Su P, Piccini P. Imaging of microglia in patients with neurodegenerative disorders. Front Pharmacol. 2012; 3: 96.

[464]

Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 1997; 19: 939-45.

[465]

Crews L, Rockenstein E, Masliah E. APP transgenic modeling of Alzheimer’s disease: mechanisms of neurodegeneration and aberrant neurogenesis. Brain Struct Funct. 2010; 214: 111-26.

[466]

Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998; 4: 97-100.

[467]

Rockenstein E, Mallory M, Mante M, Sisk A, Masliaha E. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). J Neurosci Res. 2001; 66: 573-82.

[468]

Navarro G, Borroto-Escuela D, Angelats E, Etayo Í, Reyes-Resina I, Pulido-Salgado M, et al. Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer’s disease and levodopa-induced dyskinesia. Brain Behav Immun. 2018; 67: 139-51.

[469]

Tang Y, Le W. Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases. Mol Neurobiol. 2016; 53: 1181-94.

[470]

Cherry JD, Olschowka JA, O’Banion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014; 11: 98.

[471]

Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, et al. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat Neurosci. 2014; 17: 131-43.

[472]

Serrano-Pozo A, Mielke ML, Gómez-Isla T, Betensky RA, Growdon JH, Frosch MP, et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer’s disease. Am J Pathol. 2011; 179: 1373-84.

[473]

Tejera D, Heneka MT. Microglia in Alzheimer’s disease: the good, the bad and the ugly. Curr Alzheimer Res. 2016; 13: 370-80.

[474]

Aires ID, Boia R, Rodrigues-Neves AC, Madeira MH, Marques C, Ambrósio AF, et al. Blockade of microglial adenosine A2A receptor suppresses elevated pressure-induced inflammation, oxidative stress, and cell death in retinal cells. Glia. 2019; 67: 896-914.

[475]

Madeira MH, Boia R, Elvas F, Martins T, Cunha RA, Ambrósio AF, et al. Selective A2A receptor antagonist prevents microglia-mediated neuroinflammation and protects retinal ganglion cells from high intraocular pressure-induced transient ischemic injury. Transl Res. 2016; 169: 112-28.

[476]

Merighi S, Borea PA, Varani K, Vincenzi F, Travagli A, Nigro M, et al. Pathophysiological Role and Medicinal Chemistry of A2A Adenosine Receptor Antagonists in Alzheimer’s Disease. Molecules. 2022; 27: 2680.

[477]

Armentero MT, Pinna A, Ferré S, Lanciego JL, Müller CE, Franco R. Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson’s disease. Pharmacol Ther. 2011; 132: 280-99.

[478]

Ikeda K, Kurokawa M, Aoyama S, Kuwana Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson’s disease. J Neurochem. 2002; 80: 262-70.

[479]

Sako W, Murakami N, Motohama K, Izumi Y, Kaji R. The effect of istradefylline for Parkinson's disease: A meta-analysis. Sci Rep. 2017; 7: 18018.

[480]

Jenner P. An overview of adenosine A2A receptor antagonists in Parkinson’s disease. Int Rev Neurobiol. 2014; 119: 71-86.

[481]

Mori A, Chen J, Uchida S, Durlach C, King SM, Jenner P. The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson’s Disease. Molecules. 2022; 27: 2366.

[482]

Jenner P, Mori A, Aradi SD, Hauser RA. Istradefylline - a first generation adenosine A2A antagonist for the treatment of Parkinson’s disease. Expert Rev Neurother. 2021; 21: 317-33.

[483]

Angulo E, Casadó V, Mallol J, Canela EI, Viñals F, Ferrer I, et al. A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathol. 2003; 13: 440-51.

[484]

Saura J, Angulo E, Ejarque A, Casadó V, Tusell JM, Moratalla R, et al. Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. J Neurochem. 2005; 95: 919-29.

[485]

Doke RR, Lamkhade GJ, Vinchurkar K, Singh S. Demystifying the Role of Neuroinflammatory Mediators as Biomarkers for Diagnosis, Prognosis, and Treatment of Alzheimer’s Disease: A Review. ACS Pharmacol Transl Sci. 2024; 7: 2987-3003.

[486]

Colonna M, Wang Y. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci. 2016; 17: 201-7.

[487]

Dagher NN, Najafi AR, Kayala KMN, Elmore MRP, White TE, Medeiros R, et al. Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice. J Neuroinflammation. 2015; 12: 139.

[488]

Fan X, Ma W, Zhang Y, Zhang L. P2X7 Receptor (P2X7R) of Microglia Mediates Neuroinflammation by Regulating (NOD)-Like Receptor Protein 3 (NLRP3) Inflammasome-Dependent Inflammation After Spinal Cord Injury. Med Sci Monit. 2020; 26: e925491.

[489]

Haynes SE, Hollopeter G, Yang G, Kurpius D, Dailey ME, Gan W, et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat Neurosci. 2006; 9: 1512-9.

[490]

Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, et al. Synaptic pruning by microglia is necessary for normal brain development. Science. 2011; 333: 1456-8.

[491]

Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron. 2012; 74: 691-705.

[492]

Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FMV. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci. 2007; 10: 1538-43.

[493]

Masuda T, Sankowski R, Staszewski O, Böttcher C, Amann L, Sagar, et al. Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution. Nature. 2019; 566: 388-92.

[494]

Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013; 19: 1584-96.

[495]

Zhao Z, Rocha NP, Salem H, Diniz BS, Teixeira AL. The association between systemic lupus erythematosus and dementia A meta-analysis. Dement Neuropsychol. 2018; 12: 143-51.

[496]

Rundell JR, Wise MG. Neurosyphilis: a psychiatric perspective. Psychosomatics. 1985; 26: 287-90, 295.

[497]

Janssen RS, Saykin AJ, Cannon L, Campbell J, Pinsky PF, Hessol NA, et al. Neurological and neuropsychological manifestations of HIV-1 infection: association with AIDS-related complex but not asymptomatic HIV-1 infection. Ann Neurol. 1989; 26: 592-600.

[498]

Taquet M, Todd JA, Harrison PJ. Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections. NPJ Vaccines. 2025; 10: 130.

[499]

Goedert M. Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein. Science. 2015; 349: 1255555.

[500]

Iadecola C, Duering M, Hachinski V, Joutel A, Pendlebury ST, Schneider JA, et al. Vascular Cognitive Impairment and Dementia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019; 73: 3326-44.

[501]

Mondello S, Schmid K, Berger RP, Kobeissy F, Italiano D, Jeromin A, et al. The challenge of mild traumatic brain injury: role of biochemical markers in diagnosis of brain damage. Med Res Rev. 2014; 34: 503-31.

[502]

Rao V, Bhushan R, Kumari P, Cheruku SP, Ravichandiran V, Kumar N. Chemobrain: A review on mechanistic insight, targets and treatments. Adv Cancer Res. 2022; 155: 29-76.

[503]

Loi SM, Cations M, Velakoulis D. Young-onset dementia diagnosis, management and care: a narrative review. Med J Aust. 2023; 218: 182-9.

[504]

Cacace R, Sleegers K, Broeckhoven CV. Molecular genetics of early-onset Alzheimer's disease revisited. Alzheimers Dement. 2016; 12: 733-48.

[505]

Carson RE, Naganawa M, Toyonaga T, Koohsari S, Yang Y, Chen M, et al. Imaging of Synaptic Density in Neurodegenerative Disorders. J Nucl Med. 2022; 63: 60S-7S.

[506]

Woodcock J, Buckman S, Goodsaid F, Walton MK, Zineh I. Qualifying biomarkers for use in drug development: a US Food and Drug Administration overview. Expert Opin Med Diagn. 2011; 5: 369-74.

[507]

Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement. 2011; 7: 367-85.

[508]

Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, et al. Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012; 11: 241-9.

[509]

Withington CG, Turner RS. Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer’s Disease. Front Neurol. 2022; 13: 862369.

[510]

Oh ES. Dementia. Ann Intern Med. 2024; 177: ITC161-76.

[511]

Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189-98.

[512]

Bohnen NI, Kuwabara H, Constantine GM, Mathis CA, Moore RY. Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease. Neurosci Lett. 2007; 424: 185-9.

[513]

Matsui H, Nishinaka K, Oda M, Hara N, Komatsu K, Kubori T, et al. Wisconsin Card Sorting Test and brain perfusion imaging in Parkinson's disease. Parkinsonism Relat Disord. 2006; 12: 273-8.

[514]

Titus MN, Gall NG, Yerxa EJ, Roberson TA, Mack W. Correlation of perceptual performance and activities of daily living in stroke patients. Am J Occup Ther. 1991; 45: 410-8.

[515]

Bennett-Levy J. Determinants of performance on the Rey-Osterrieth Complex Figure Test: an analysis, and a new technique for single-case assessment. Br J Clin Psychol. 1984; 23: 109-19.

[516]

Elwood RW. The California Verbal Learning Test: psychometric characteristics and clinical application. Neuropsychol Rev. 1995; 5: 173-201.

[517]

Barlet BD, Hauson AO, Pollard AA, Zhang EZ, Nemanim NM, Sarkissians S, et al. Neuropsychological Performance in Alzheimer’s Disease versus Late-Life Depression: A Systematic Review and Meta-Analysis. Arch Clin Neuropsychol. 2023; 38: 991-1016.

[518]

Doty RL. Office procedures for quantitative assessment of olfactory function. Am J Rhinol. 2007; 21: 460-73.

[519]

Uddin MS, Hasana S, Hossain MF, Islam MS, Behl T, Perveen A, et al. Molecular Genetics of Early- and Late-Onset Alzheimer’s Disease. Curr Gene Ther. 2021; 21: 43-52.

[520]

Randa NC, Bora E, Ataman E, Öz O, Yener G, Ülgenalp A. Identification of PSEN1 and PSEN2 Gene Variants and Clinical Findings with the Literature. Int J Neurodegener Dis. 2019; 2: 007.

[521]

Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993; 90: 9649-53.

[522]

Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993; 90: 8098-102.

[523]

Šerý O, Janoutová J, Ewerlingová L, Hálová A, Lochman J, Janout V, et al. CD36 gene polymorphism is associated with Alzheimer's disease. Biochimie. 2017; 135: 46-53.

[524]

Dobri A, Dudău M, Enciu A, Hinescu ME. CD36 in Alzheimer’s Disease: An Overview of Molecular Mechanisms and Therapeutic Targeting. Neuroscience. 2021; 453: 301-11.

[525]

Šerý O, Zeman T, Sheardová K, Vyhnálek M, Marková H, Laczó J, et al. Six genetically linked mutations in the CD36 gene significantly delay the onset of Alzheimer’s disease. Sci Rep. 2022; 12: 10994.

[526]

Luo Z, Lv L. Impacts of CD36 Variants on Plasma Lipid Levels and the Risk of Early-Onset Coronary Artery Disease: A Systematic Review and Meta-Analysis. Cardiovasc Ther. 2016; 2016: 8098173.

[527]

Zhang Z, Wu S, Stenoien DL, Paša-Tolić L. High-throughput proteomics. Annu Rev Anal Chem (Palo Alto Calif). 2014; 7: 427-54.

[528]

Meissner F, Geddes-McAlister J, Mann M, Bantscheff M. The emerging role of mass spectrometry-based proteomics in drug discovery. Nat Rev Drug Discov. 2022; 21: 637-54.

[529]

Sanghai N, Tranmer GK. Use of Proteomics to Explore Biomarkers of Amyotrophic Lateral Sclerosis (ALS): Proof of Principle from Humanized SOD1 Mouse to Human ALS. ACS Pharmacol Transl Sci. 2025; 8: 2415-30.

[530]

Thakor VS, Tyagi A, Lee JM Jr, Coffman F, Mittal R. Alois Alzheimer (1864-1915): The Father of Modern Dementia Research and the Discovery of Alzheimer’s Disease. Cureus. 2024; 16: e71731.

[531]

Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord. 2013; 6: 19-33.

[532]

Franco R. Plasma p-tau217 in Alzheimer’s disease is a dynamic gauge of progression heterogeneity, not a baseline stratifier. Explor Neuroprot Ther. 2025; 5: 1004118.

[533]

Kirsebom B, Gonzalez-Ortiz F, Vigneswaran S, Bråthen G, Skogseth RE, Gísladóttir B, et al. Repeated plasma p-tau217 measurements to monitor clinical progression heterogeneity. Alzheimers Dement. 2025; 21: e70319.

[534]

Bernal-Casas D, Serrano-Marín J, Sánchez-Navés J, Oller JM, Franco R. Advancing Personalized Medicine by Analytical Means: Selection of Three Metabolites That Allows Discrimination between Glaucoma, Diabetes, and Controls. Metabolites. 2024; 14: 149.

[535]

Stefanini E, Iglesias A, Serrano-Marín J, Sánchez-Navés J, Alkozi HA, Pallàs M, et al. Machine Learning Approach to Select Small Compounds in Plasma as Predictors of Alzheimer’s Disease. Int J Mol Sci. 2025; 26: 6991.

[536]

Bakulski KM, Seo YA, Hickman RC, Brandt D, Vadari HS, Hu H, et al. Heavy Metals Exposure and Alzheimer’s Disease and Related Dementias. J Alzheimers Dis. 2020; 76: 1215-42.

[537]

Inoue Y, Shue F, Bu G, Kanekiyo T. Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease. Mol Neurodegener. 2023; 18: 46.

[538]

Roytman M, Mashriqi F, Al-Tawil K, Schulz PE, Zaharchuk G, Benzinger TLS, et al. Amyloid-Related Imaging Abnormalities: An Update. AJR Am J Roentgenol. 2023; 220: 562-74.

[539]

Jeong SY, Suh CH, Lim J, Shim WH, Heo H, Choi Y, et al. Incidence of Amyloid-Related Imaging Abnormalities in Phase III Clinical Trials of Anti-Amyloid-β Immunotherapy: An Updated Meta-Analysis. Neurology. 2025; 104: e213483.

[540]

Smith AM, Obuchowski NA, Foster NL, Klein G, Mozley PD, Lammertsma AA, et al. The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification. J Nucl Med. 2023; 64: 294-303.

[541]

Biomarkers Inventory - ESR | European Society of Radiology [Internet]. European Society of Radiology; c2025 [cited 2025 Dec 10]. Available from: https://www.myesr.org/research/biomarkers-inventory/

[542]

Sengupta U, Kayed R. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. Prog Neurobiol. 2022; 214: 102270.

[543]

Hansen N, Rauter C, Wiltfang J. Blood Based Biomarker for Optimization of Early and Differential Diagnosis of Alzheimer’s Dementia. Fortschr Neurol Psychiatr. 2022; 90: 326-35.

[544]

Jack CR, Wiste HJ, Algeciras-Schimnich A, Figdore DJ, Schwarz CG, Lowe VJ, et al. Predicting amyloid PET and tau PET stages with plasma biomarkers. Brain. 2023; 146: 2029-44.

[545]

Pais MV, Forlenza OV, Diniz BS. Plasma Biomarkers of Alzheimer’s Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice. J Alzheimers Dis Rep. 2023; 7: 355-80.

[546]

Blennow K, Zetterberg H. Biomarkers for Alzheimer’s disease: current status and prospects for the future. J Intern Med. 2018; 284: 643-63.

[547]

Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007; 64: 343-9.

[548]

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018; 14: 535-62.

[549]

Bellomo G, De Luca CMG, Paoletti FP, Gaetani L, Moda F, Parnetti L. α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward. Neurology. 2022; 99: 195-205.

[550]

Stankovic I, Kuijpers M, Kaufmann H. An update on multiple system atrophy. Curr Opin Neurol. 2024; 37: 400-8.

[551]

Gibbons CH, Freeman R, Bellaire B, Adler CH, Moore D, Levine T. Synuclein-One study: skin biopsy detection of phosphorylated α-synuclein for diagnosis of synucleinopathies. Biomark Med. 2022; 16: 499-509.

[552]

Vacchi E, Lazzarini E, Pinton S, Chiaro G, Disanto G, Marchi F, et al. Tau protein quantification in skin biopsies differentiates tauopathies from alpha-synucleinopathies. Brain. 2022; 145: 2755-68.

[553]

Donadio V, Wang Z, Incensi A, Rizzo G, Fileccia E, Vacchiano V, et al. In Vivo Diagnosis of Synucleinopathies: A Comparative Study of Skin Biopsy and RT-QuIC. Neurology. 2021; 96: e2513-24.

[554]

Dellarole IL, Vacchi E, Ruiz-Barrio I, Pinton S, Raimondi A, Rossi S, et al. Tau seeding activity in skin biopsy differentiates tauopathies from synucleinopathies. NPJ Parkinsons Dis. 2024; 10: 116.

[555]

Zoia CP, Tagliabue E, Isella V, Begni B, Fumagalli L, Brighina L, et al. Fibroblast glutamate transport in aging and in AD: correlations with disease severity. Neurobiol Aging. 2005; 26: 825-32.

[556]

Braun J, Tuomanen E, Cleveland J. Neuroprotection by caspase inhibitors. Expert Opin Investig Drugs. 1999; 8: 1599-610.

[557]

Legos JJ, Lee D, Erhardt JA. Caspase inhibitors as neuroprotective agents. Expert Opin Emerg Drugs. 2001; 6: 81-94.

[558]

Olmastroni E, Molari G, Beni ND, Colpani O, Galimberti F, Gazzotti M, et al. Statin use and risk of dementia or Alzheimer’s disease: a systematic review and meta-analysis of observational studies. Eur J Prev Cardiol. 2022; 29: 804-14.

[559]

Johansson H, Hagströmer M, Grooten WJA, Franzén E. Exercise-Induced Neuroplasticity in Parkinson’s Disease: A Metasynthesis of the Literature. Neural Plast. 2016; 2016: 8961493.

[560]

Singulani MP, Ferreira AFF, Figueroa PS, Cuyul-Vásquez I, Talib LL, Britto LR, et al. Lithium and disease modification: A systematic review and meta-analysis in Alzheimer’s and Parkinson’s disease. Ageing Res Rev. 2024; 95: 102231.

[561]

Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2016; 2016: CD001447.

[562]

Postuma RB, Iranzo A, Hu M, Högl B, Boeve BF, Manni R, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain. 2019; 142: 744-59.

[563]

O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006; 59: 467-77.

[564]

Stinton C, McKeith I, Taylor J, Lafortune L, Mioshi E, Mak E, et al. Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. Am J Psychiatry. 2015; 172: 731-42.

[565]

Aronowski J, Zhao X. Molecular pathophysiology of cerebral hemorrhage: secondary brain injury. Stroke. 2011; 42: 1781-6.

[566]

Casson RJ, Chidlow G, Ebneter A, Wood JPM, Crowston J, Goldberg I. Translational neuroprotection research in glaucoma: a review of definitions and principles. Clin Exp Ophthalmol. 2012; 40: 350-7.

[567]

Franco R, Garrigós C, Lillo J, Rivas-Santisteban R. The Potential of Metabolomics to Find Proper Biomarkers for Addressing the Neuroprotective Efficacy of Drugs Aimed at Delaying Parkinson’s and Alzheimer’s Disease Progression. Cells. 2024; 13: 1288.

[568]

Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P, et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ. 2007; 334: 197.

[569]

Pound P, Ritskes-Hoitinga M. Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail. J Transl Med. 2018; 16: 304.

[570]

Macleod MR, Lawson McLean A, Kyriakopoulou A, Serghiou S, de Wilde A, Sherratt N, et al. Risk of Bias in Reports of In Vivo Research: A Focus for Improvement. PLoS Biol. 2015; 13: e1002273.

[571]

Franco R, Cedazo-Minguez A. Successful therapies for Alzheimer’s disease: why so many in animal models and none in humans? Front Pharmacol. 2014; 5: 146.

[572]

Barros PR, Costa TJ, Akamine EH, Tostes RC. Vascular Aging in Rodent Models: Contrasting Mechanisms Driving the Female and Male Vascular Senescence. Front Aging. 2021; 2: 727604.

[573]

Becker JB, Arnold AP, Berkley KJ, Blaustein JD, Eckel LA, Hampson E, et al. Strategies and methods for research on sex differences in brain and behavior. Endocrinology. 2005; 146: 1650-73.

[574]

Jackson SJ, Andrews N, Ball D, Bellantuono I, Gray J, Hachoumi L, et al. Does age matter? The impact of rodent age on study outcomes. Lab Anim. 2017; 51: 160-9.

[575]

Maida CD, Daidone M, Pacinella G, Norrito RL, Pinto A, Tuttolomondo A. Diabetes and Ischemic Stroke: An Old and New Relationship an Overview of the Close Interaction between These Diseases. Int J Mol Sci. 2022; 23: 2397.

[576]

Osborne BF, Turano A, Schwarz JM. Sex Differences in the Neuroimmune System. Curr Opin Behav Sci. 2018; 23: 118-23.

[577]

Leclerc JL, Garcia JM, Diller MA, Carpenter A, Kamat PK, Hoh BL, et al. A Comparison of Pathophysiology in Humans and Rodent Models of Subarachnoid Hemorrhage. Front Mol Neurosci. 2018; 11: 71.

[578]

Morais A, Locascio JJ, Sansing LH, Lamb J, Nagarkatti K, Imai T, et al.; SPAN Investigators. Embracing Heterogeneity in The Multicenter Stroke Preclinical Assessment Network (SPAN) Trial. Stroke. 2023; 54: 620-31.

[579]

Depoorter A, Neumann RP, Barro C, Fisch U, Weber P, Kuhle J, et al. Neurofilament Light Chain: Blood Biomarker of Neonatal Neuronal Injury. Front Neurol. 2018; 9: 984.

[580]

Gaetani L, Blennow K, Calabresi P, Filippo MD, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019; 90: 870-81.

[581]

Loeffler T, Schilcher I, Flunkert S, Hutter-Paier B. Neurofilament-Light Chain as Biomarker of Neurodegenerative and Rare Diseases With High Translational Value. Front Neurosci. 2020; 14: 579.

[582]

Shahzad M, Stern AD. Participants in the FDA's Biomarker Qualification Program. Clin Pharmacol Ther. 2025; 118: 80-4.

[583]

Abukuri DN. Novel Biomarkers for Alzheimer's Disease: Plasma Neurofilament Light and Cerebrospinal Fluid. Int J Alzheimers Dis. 2016; 2016: 6668159.

[584]

Andraos C, Siddiqi A, Brazdzionis J, Siddiqi J. Limitations of the Glasgow Coma Scale: Challenges and Considerations. Cureus. 2025; 17:e78900.

[585]

Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018; 14: 577-89.

[586]

Tauskela JS, Blondeau N. How to Pick a Neuroprotective Drug in Stroke Without Losing Your Mind? Life (Basel). 2025; 15: 883.

[587]

Sugandhi VV, Gadhave DG, Ugale AR, Kulkarni N, Nangare SN, Patil HP, et al. Advances in Alzheimer’s therapy: Exploring neuropathological mechanisms to revolutionize the future therapeutic landscape. Ageing Res Rev. 2025; 109: 102775.

[588]

Müller-Nedebock AC, Dekker MCJ, Farrer MJ, Hattori N, Lim S, Mellick GD, et al. Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson’s disease. NPJ Parkinsons Dis. 2023; 9: 110.

[589]

Jain S, Acharya R, Verma L, Chauhan A. Harnessing Metabolism to Combat Neurodegeneration: Strategies for Reversing Age-Related Cognitive Decline. ACS Pharmacol Transl Sci. 2025; 8: 2868-86.

[590]

Winchester LM, Harshfield EL, Shi L, Badhwar A, Khleifat AA, Clarke N, et al. Artificial intelligence for biomarker discovery in Alzheimer’s disease and dementia. Alzheimers Dement. 2023; 19: 5860-71.

[591]

Beheshti I, Sone D, Leung CK. Advances of Artificial Intelligence in Neuroimaging. Brain Sci. 2025; 15: 351.

[592]

Bhattacharya S, Prusty S, Pande SP, Gulhane M, Lavate SH, Rakesh N, et al. Integration of multimodal imaging data with machine learning for improved diagnosis and prognosis in neuroimaging. Front Hum Neurosci. 2025; 19: 1552178.

[593]

Cao Y, Xu Y, Cao M, Chen N, Zeng Q, Lai MKP, et al. Fluid-based biomarkers for neurodegenerative diseases. Ageing Res Rev. 2025; 108: 102739.

[594]

Milà-Alomà M, Salvadó G, Gispert JD, Vilor-Tejedor N, Grau-Rivera O, Sala-Vila A, et al. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer’s continuum. Alzheimers Dement. 2020; 16: 1358-71.

[595]

Buccilli B, Alan A, Baha’ A, Shahzad A, Almealawy YF, Chisvo NS, et al. Neuroprotection strategies in traumatic brain injury: Studying the effectiveness of different clinical approaches. Surg Neurol Int. 2024; 15: 29.

[596]

Bhaumik DK, Wang Y, Yen P, Ajilore OA. Development of a Bayesian multimodal model to detect biomarkers in neuroimaging studies. Front Neuroimaging. 2023; 2: 1147508.

[597]

Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015; 385: 2255-63.

[598]

Kivipelto M, Mangialasche F, Snyder HM, Allegri R, Andrieu S, Arai H, et al. World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. Alzheimers Dement. 2020; 16: 1078-94.

[599]

Guidetti M, Bertini A, Pirone F, Sala G, Signorelli P, Ferrarese C, et al. Neuroprotection and Non-Invasive Brain Stimulation: Facts or Fiction? Int J Mol Sci. 2022; 23: 13775.

[600]

Zhao G, Zhang H, Xu Y, Chu X. Research on magnetic resonance imaging in diagnosis of Alzheimer’s disease. Eur J Med Res. 2024; 29: 632.

[601]

Lagarde J, Olivieri P, Tonietto M, Tissot C, Rivals I, Gervais P, et al. Tau-PET imaging predicts cognitive decline and brain atrophy progression in early Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2022; 93: 459-67.

[602]

Leone R, Kobeleva X ; Initiative ADN. White matter hyperintensities contribute to early cortical thinning in addition to tau in aging. Neurobiol Aging. 2025; 155: 66-77.

[603]

Zarkali A, Thomas GEC, Zetterberg H, Weil RS. Neuroimaging and fluid biomarkers in Parkinson’s disease in an era of targeted interventions. Nat Commun. 2024; 15: 5661.

[604]

Deckers K, Zwan MD, Soons LM, Waterink L, Beers S, Houdt Sv, et al. A multidomain lifestyle intervention to maintain optimal cognitive functioning in Dutch older adults-study design and baseline characteristics of the FINGER-NL randomized controlled trial. Alzheimers Res Ther. 2024; 16: 126.

[605]

Huang G, Chen X, Liao C. AI-Driven Wearable Bioelectronics in Digital Healthcare. Biosensors (Basel). 2025; 15: 410.

[606]

Chodankar D, Raval TK, Jeyaraj J. The role of remote data capture, wearables, and digital biomarkers in decentralized clinical trials. Perspect Clin Res. 2024; 15: 38-41.

[607]

Arya SS, Dias SB, Jelinek HF, Hadjileontiadis LJ, Pappa A. The convergence of traditional and digital biomarkers through AI-assisted biosensing: A new era in translational diagnostics? Biosens Bioelectron. 2023; 235: 115387.

[608]

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer’s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2013; 9: e111-94.

[609]

Vinukonda ER, Jagadesh BN. An integrated deep learning model for early and multi-class diagnosis of Alzheimer’s disease from MRI scans. Sci Rep. 2025; 15: 17169.

[610]

Iulita MF, Streel E, Harrison J. Digital biomarkers: Redefining clinical outcomes and the concept of meaningful change. Alzheimers Dement (N Y). 2025; 11:e70114.

[611]

Marey A, Arjmand P, Alerab ADS, Eslami MJ, Saad AM, Sanchez N, et al. Explainability, transparency and black box challenges of AI in radiology: impact on patient care in cardiovascular radiology. Egypt J Radiol Nucl Med. 2024; 55: 183.

[612]

Neurotechnology and neurorights - Privacy’s last frontier [Internet]. European Parliament; [cited 2025 Jul 17]. Available from: https://www.europarl.europa.eu/thinktank/de/events/details/neurotechnology-and-neurorights-privacy-/20231019WKS05721

[613]

Ienca M, Andorno R. Towards new human rights in the age of neuroscience and neurotechnology. Life Sci Soc Policy. 2017; 13: 5.

[614]

Hanslmayr S. The promises and challenges of neurotechnology to improve human health and cognition. PLoS Biol. 2024; 22: e3002903.

[615]

O’Riordan KJ, Moloney GM, Keane L, Clarke G, Cryan JF. The gut microbiota-immune-brain axis: Therapeutic implications. Cell Rep Med. 2025; 6: 101982.

[616]

Hyman B, Tanzi RE. Effects of Species-Specific Genetics on Alzheimer’s Mouse Models. Neuron. 2019; 101: 351-2.

[617]

Yadav S, Raj RG. Parkinson’s disease and the gut microbiota connection: unveiling dysbiosis and exploring therapeutic horizons. Neuroscience. 2025; 581: 1-15.

[618]

Jin D, Morton JT, Bonneau R. Meta-analysis of the human gut microbiome uncovers shared and distinct microbial signatures between diseases. mSystems. 2024; 9: e0029524.

[619]

Rob M, Yousef M, Lakshmanan AP, Mahboob A, Terranegra A, Chaari A. Microbial signatures and therapeutic strategies in neurodegenerative diseases. Biomed Pharmacother. 2025; 184: 117905.

[620]

Sun J, Zhang Y. Microbiome and micronutrient in ALS: From novel mechanisms to new treatments. Neurotherapeutics. 2024; 21: e00441.

[621]

Yang EJ. The Emerging Role of the Brain-Gut Axis in Amyotrophic Lateral Sclerosis: Pathogenesis, Mechanisms, and Therapeutic Perspectives. Int J Mol Sci. 2025; 26: 8419.

[622]

Hou S, Yu J, Li Y, Zhao D, Zhang Z. Advances in Fecal Microbiota Transplantation for Gut Dysbiosis-Related Diseases. Adv Sci (Weinh). 2025; 12: e2413197.

[623]

Olajide TS, Ijomone OM. Targeting gut microbiota as a therapeutic approach for neurodegenerative diseases. Neuroprotection. 2025; 3: 120-30.

[624]

Lei W, Cheng Y, Liu X, Gao J, Zhu Z, Ding W, et al. Gut microbiota-driven neuroinflammation in Alzheimer’s disease: from mechanisms to therapeutic opportunities. Front Immunol. 2025; 16: 1582119.

[625]

Abdelhamid M, Counts SE, Zhou C, Hida H, Kim J, Michikawa M, et al. Protective Effects of Bifidobacterium Breve MCC1274 as a Novel Therapy for Alzheimer's Disease. Nutrients. 2025; 17: 558.

[626]

Renesteen E, Boyajian JL, Islam P, Kassab A, Abosalha A, Makhlouf S, et al. Microbiome Engineering for Biotherapeutic in Alzheimer's Disease Through the Gut-Brain Axis: Potentials and Limitations. Int J Mol Sci. 2025; 26: 5351.

[627]

O’Riordan KJ, Collins MK, Moloney GM, Knox EG, Aburto MR, Fülling C, et al. Short chain fatty acids: Microbial metabolites for gut-brain axis signalling. Mol Cell Endocrinol. 2022; 546: 111572.

[628]

Cheng J, Hu H, Ju Y, Liu J, Wang M, Liu B, et al. Gut microbiota-derived short-chain fatty acids and depression: deep insight into biological mechanisms and potential applications. Gen Psychiatr. 2024; 37: e101374.

[629]

Barnes LL. Biomarkers for Alzheimer Dementia in Diverse Racial and Ethnic Minorities-A Public Health Priority. JAMA Neurol. 2019; 76: 251-3.

[630]

Xiong C, Schindler S, Luo J, Morris J, Bateman R, Holtzman D, et al. Baseline levels and longitudinal rates of change in plasma Aβ42/40 among self-identified Black/African American and White individuals. Res Sq [Preprint]. 2024; rs.3.rs-3783571.

[631]

Kolbe A. HHS Actions to Enhance Diversity in Clinical Research: Issue Brief. Washington (DC): Office of the Assistant Secretary for Planning and Evaluation (ASPE); 2024.

[632]

Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups. Bibbins-Domingo K, Helman A, editors. National Academies of Sciences, Engineering, and Medicine; Policy and Global Affairs; Committee on Women in Science, Engineering, and Medicine; Committee on Improving the Representation of Women and Underrepresented Minorities in Clinical Trials and Research. Washington (DC): National Academies Press (US); 2022.

[633]

Malekzadeh A, Michels K, Wolfman C, Anand N, Sturke R. Strengthening research capacity in LMICs to address the global NCD burden. Glob Health Action. 2020; 13: 1846904.

[634]

Rossi SL, Subramanian P, Bovenkamp DE. The future is precision medicine-guided diagnoses, preventions and treatments for neurodegenerative diseases. Front Aging Neurosci. 2023; 15: 1128619.

[635]

Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 2018; 16: 29.

[636]

Hammouri H, Salman M, Ali M, Abdel Muhsen R. Advances in Clinical Trial Design: Employing Adaptive Multiple Testing and Neyman Allocation for Unequal Samples. Mathematics. 2025; 13: 1273.

[637]

Molla G, Bitew M. Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data Generation, Main Hurdles, and Future Perspectives. Biomedicines. 2024; 12: 2750.

[638]

Robles AI, Harris CC. Integration of multiple “OMIC” biomarkers: A precision medicine strategy for lung cancer. Lung Cancer. 2017; 107: 50-8.

[639]

Iacovitti L. Neuroprotection: Basic mechanisms and translational potential. Brain Res. 2015; 1628: 245-6.

PDF (5015KB)

20

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉